diff --git a/CHANGELOG.md b/CHANGELOG.md index dacf19e..f14a86e 100644 --- a/CHANGELOG.md +++ b/CHANGELOG.md @@ -5,6 +5,38 @@ All notable changes to `table2rules` are documented here. Dates are in ## [Unreleased] +## [0.6.1] — 2026-06-14 + +### Fixed + +- **Label-only rows are now threaded as row-group headers.** 0.6.0's row-group + threading only handled the *full-width band* form (a cell spanning the value + region / `scope="rowgroup"`). The **label-only-row** form — a body row whose + value columns are empty while a single leading label cell carries text + (`9. Trip Cancellation | (empty) | (empty)`), pervasive in `Label | Value` + financial/insurance schedules — was missed: it was emitted as an orphaned + `is_label` rule and the values beneath it lost their group identity. Such a + row is now promoted to a row-group ancestor and threaded into every value line + under it, until the next label-only row at the same level: + + ``` + 10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Value Plan: 100 + ``` + + Detection stays geometric and additive to the existing band path: + - A row with no value-bearing `` but exactly **one** non-empty label + source cell is a group header. Consecutive label-only rows nest in order + (a title followed by a description), and the two forms compose — a + full-width section band and a label-only group nest consistently. + - The **single-label-cell** requirement separates a group header from a data + row whose designated value columns merely happen to be empty: a summary row + spreading several values across its label cells (`Total | n=4`, or a row + under a header that over-promoted numeric columns to row labels) keeps the + `is_label` preservation path, so its cells are never invented into a + breadcrumb and misattributed onto the rows below. + - A trailing label-only row with no value rows beneath it stays a label + (parity with the full-width-note guard) — no empty group is created. + ## [0.6.0] — 2026-06-11 ### Added diff --git a/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt b/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt index fa9d61c..a9b1619 100644 --- a/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt +++ b/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt @@ -1,16 +1,14 @@ -Current assets: -Cash and equivalents | 2024: 4,210 -Cash and equivalents | 2023: 3,850 -Accounts receivable | 2024: 12,400 -Accounts receivable | 2023: 11,200 -Inventory | 2024: 8,900 -Inventory | 2023: 9,100 -Total current assets | 2024: 25,510 -Total current assets | 2023: 24,150 -Non-current assets: -Property, plant & equipment | 2024: 42,100 -Property, plant & equipment | 2023: 38,900 -Goodwill | 2024: 18,200 -Goodwill | 2023: 18,200 -Total non-current assets | 2024: 60,300 -Total non-current assets | 2023: 57,100 \ No newline at end of file +Current assets: > Cash and equivalents | 2024: 4,210 +Current assets: > Cash and equivalents | 2023: 3,850 +Current assets: > Accounts receivable | 2024: 12,400 +Current assets: > Accounts receivable | 2023: 11,200 +Current assets: > Inventory | 2024: 8,900 +Current assets: > Inventory | 2023: 9,100 +Current assets: > Total current assets | 2024: 25,510 +Current assets: > Total current assets | 2023: 24,150 +Non-current assets: > Property, plant & equipment | 2024: 42,100 +Non-current assets: > Property, plant & equipment | 2023: 38,900 +Non-current assets: > Goodwill | 2024: 18,200 +Non-current assets: > Goodwill | 2023: 18,200 +Non-current assets: > Total non-current assets | 2024: 60,300 +Non-current assets: > Total non-current assets | 2023: 57,100 \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt new file mode 100644 index 0000000..4bb1d66 --- /dev/null +++ b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt @@ -0,0 +1,5 @@ +Region X > Asia > Japan | A: 10 +Region X > Asia > Japan | B: 20 +Region X > Asia > Korea | A: 30 +Region X > Asia > Korea | B: 40 +Total > n=4 \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt new file mode 100644 index 0000000..f5678b4 --- /dev/null +++ b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt @@ -0,0 +1,7 @@ +9. Trip Cancellation > If the trip is cancelled | Maximum limit (S$) > Value Plan: 5,000 +9. Trip Cancellation > If the trip is cancelled | Maximum limit (S$) > Economy Plan: 10,000 +10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Value Plan: 100 +10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Economy Plan: 150 +10. Travel Delay > If the departure is delayed > 2. Child insured person | Maximum limit (S$) > Value Plan: 50 +10. Travel Delay > If the departure is delayed > 2. Child insured person | Maximum limit (S$) > Economy Plan: 75 +11. Trip Postponement \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt b/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt index 40f4539..0537eea 100644 --- a/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt +++ b/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt @@ -1,9 +1,7 @@ -1. Accidental death and permanent disability -Each adult insured person under 70 | Sum Insured: S$250,000 -Each child insured person | Sum Insured: S$100,000 -2. Public transport double indemnity -Each adult insured person under 70 | Sum Insured: S$500,000 -Each child insured person | Sum Insured: S$200,000 +1. Accidental death and permanent disability > Each adult insured person under 70 | Sum Insured: S$250,000 +1. Accidental death and permanent disability > Each child insured person | Sum Insured: S$100,000 +2. Public transport double indemnity > Each adult insured person under 70 | Sum Insured: S$500,000 +2. Public transport double indemnity > Each child insured person | Sum Insured: S$200,000 3. COVID-19 coverage extension -Each adult insured person under 70 | Sum Insured: S$50,000 -Each child insured person | Sum Insured: S$20,000 \ No newline at end of file +2. Public transport double indemnity > Each adult insured person under 70 | Sum Insured: S$50,000 +2. Public transport double indemnity > Each child insured person | Sum Insured: S$20,000 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt index 3ac5ef9..60fd956 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt @@ -1,4 +1,3 @@ -2014 2014 > Fourth Quarter | NYSECommon Stock > High: $83.90 2014 > Fourth Quarter | NYSECommon Stock > Low: $52.32 2014 > Fourth Quarter | OSECommon Stock (1) > High: 638.00 @@ -15,7 +14,6 @@ 2014 > First Quarter | NYSECommon Stock > Low: $45.95 2014 > First Quarter | OSECommon Stock (1) > High: 332.60 2014 > First Quarter | OSECommon Stock (1) > Low: 284.20 -2013 2013 > Fourth Quarter | NYSECommon Stock > High: $47.66 2013 > Fourth Quarter | NYSECommon Stock > Low: $35.97 2013 > Fourth Quarter | OSECommon Stock (1) > High: 292.60 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt index 4c1e9ea..7933a38 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2014 > $: $148,909 Operating expenses: > Research and development | Year Ended December 31, > 2014 > % ofrevenue: 25.5% Operating expenses: > Research and development | Year Ended December 31, > 2013 > $: $98,587 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt index 89b06a7..0402dd9 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2015 > $: $744,877 Revenue > Product | Year Ended December 31, > 2015 > % ofrevenue: 88.9% Revenue > Product | Year Ended December 31, > 2014 > $: $531,543 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2014 > $: 584,106 Revenue > Total revenue | Year Ended December 31, > 2014 > % ofrevenue: 100.0 Revenue > Total revenue | Change in > $: 253,485 Revenue > Total revenue | Change in > %: 43.4 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2015 > $: 263,585 Cost of revenue > Product | Year Ended December 31, > 2015 > % ofrevenue: 31.5 Cost of revenue > Product | Year Ended December 31, > 2014 > $: 174,004 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt index 1820050..fa8ac6c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2015 > $: $209,448 Operating expenses: > Research and development | Year Ended December 31, > 2015 > % ofrevenue: 25.0% Operating expenses: > Research and development | Year Ended December 31, > 2014 > $: $148,909 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt index de19f94..575fcd0 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 Operating expenses: > Research and development | Year Ended December 31, > 2017 > % ofRevenue: 21.2% Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt index 9b147c8..32cf2e6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 Operating expenses: > Research and development | Year Ended December 31, > 2016 > % ofRevenue: 24.2% Operating expenses: > Research and development | Year Ended December 31, > 2015 > $: $209,448 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt index 6f2adec..ff5e404 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2016 > $: $991,337 Revenue > Product | Year Ended December 31, > 2016 > % ofRevenue: 87.8% Revenue > Product | Year Ended December 31, > 2015 > $: $744,877 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2015 > $: 837,591 Revenue > Total revenue | Year Ended December 31, > 2015 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 291,576 Revenue > Total revenue | Change in > %: 34.8 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2016 > $: 369,768 Cost of revenue > Product | Year Ended December 31, > 2016 > % ofRevenue: 32.8 Cost of revenue > Product | Year Ended December 31, > 2015 > $: 263,585 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt index a4e2675..f3e21fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > % ofRevenue: (0.2)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2016 > $: $(3,136) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt index 478a145..b658d4b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2017 > $: $1,432,810 Revenue > Product | Year Ended December 31, > 2017 > % ofRevenue: 87.0% Revenue > Product | Year Ended December 31, > 2016 > $: $991,337 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2016 > $: 1,129,167 Revenue > Total revenue | Year Ended December 31, > 2016 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 517,019 Revenue > Total revenue | Change in > %: 45.8 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2017 > $: 538,035 Cost of revenue > Product | Year Ended December 31, > 2017 > % ofRevenue: 32.7 Cost of revenue > Product | Year Ended December 31, > 2016 > $: 369,768 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt index de19f94..575fcd0 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 Operating expenses: > Research and development | Year Ended December 31, > 2017 > % ofRevenue: 21.2% Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt index a4e2675..f3e21fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > % ofRevenue: (0.2)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2016 > $: $(3,136) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt index b6dfa72..810c2ee 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2018 > $: $1,841,100 Revenue > Product | Year Ended December 31, > 2018 > % ofRevenue: 85.6% Revenue > Product | Year Ended December 31, > 2017 > $: $1,432,810 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2017 > $: 1,646,186 Revenue > Total revenue | Year Ended December 31, > 2017 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 505,183 Revenue > Total revenue | Change in > %: 30.7 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2018 > $: 720,584 Cost of revenue > Product | Year Ended December 31, > 2018 > % ofRevenue: 33.5 Cost of revenue > Product | Year Ended December 31, > 2017 > $: 538,035 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt index 3041524..ed936fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2018 > $: $(2,701) Other income (expense), net: > Interest expense | Year Ended December 31, > 2018 > % ofRevenue: (0.1)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt index 0b46365..4ce7d3e 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2018 > $: $442,468 Operating expenses: > Research and development | Year Ended December 31, > 2018 > % ofRevenue: 20.6% Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt index c2185ba..b4998d3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt @@ -1,4 +1,3 @@ -2012 2012 > Fourth Quarter | NYSE Common Stock > High: $36.18 2012 > Fourth Quarter | NYSE Common Stock > Low: $30.26 2012 > Fourth Quarter | OSE Common Stock (1) > High: 202.50 @@ -15,7 +14,6 @@ 2012 > First Quarter | NYSE Common Stock > Low: 25.40 2012 > First Quarter | OSE Common Stock (1) > High: 183.70 2012 > First Quarter | OSE Common Stock (1) > Low: 149.30 -2011 2011 > Fourth Quarter | NYSE Common Stock > High: $30.99 2011 > Fourth Quarter | NYSE Common Stock > Low: $18.70 2011 > Fourth Quarter | OSE Common Stock (1) > High: 168.00 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt index 3a6e9b1..a098afc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2012 Balance as of December 31, 2012 > Goodwill | Vascular North America > (Dollars in thousands): $407,090 Balance as of December 31, 2012 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): $167,942 Balance as of December 31, 2012 > Goodwill | Surgical North America > (Dollars in thousands): $245,794 @@ -34,7 +33,6 @@ Balance as of December 31, 2012 > Translation adjustment | EMEA > (Dollars in th Balance as of December 31, 2012 > Translation adjustment | Asia > (Dollars in thousands): (8,917) Balance as of December 31, 2012 > Translation adjustment | All Other > (Dollars in thousands): (82) Balance as of December 31, 2012 > Translation adjustment | Total > (Dollars in thousands): (7,533) -Balance as of December 31, 2013 Balance as of December 31, 2013 > Goodwill | Vascular North America > (Dollars in thousands): 459,696 Balance as of December 31, 2013 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): 167,195 Balance as of December 31, 2013 > Goodwill | Surgical North America > (Dollars in thousands): 250,506 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt index e688882..08373ba 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2013 Balance as of December 31, 2013 > Goodwill | Vascular North America > (Dollars in thousands): $459,696 Balance as of December 31, 2013 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): $167,195 Balance as of December 31, 2013 > Goodwill | Surgical North America > (Dollars in thousands): $250,506 @@ -33,7 +32,6 @@ Balance as of December 31, 2013 > Translation adjustment | EMEA > (Dollars in th Balance as of December 31, 2013 > Translation adjustment | Asia > (Dollars in thousands): (8,220) Balance as of December 31, 2013 > Translation adjustment | All Other > (Dollars in thousands): (3,753) Balance as of December 31, 2013 > Translation adjustment | Total > (Dollars in thousands): (47,042) -Balance as of December 31, 2014 Balance as of December 31, 2014 > Goodwill | Vascular North America > (Dollars in thousands): 459,696 Balance as of December 31, 2014 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): 166,514 Balance as of December 31, 2014 > Goodwill | Surgical North America > (Dollars in thousands): 250,912 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt index 5577b8a..2fd6c2c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt @@ -26,7 +26,6 @@ Average interest rate | Year of Maturity > 2010 > (Dollars in thousands): — Average interest rate | Year of Maturity > 2011 > (Dollars in thousands): 5.6% Average interest rate | Thereafter > (Dollars in thousands): — Average interest rate | Total > (Dollars in thousands): 5.0% -Amount subject to swaps: Amount subject to swaps: > Variable to fixed | Year of Maturity > 2008 > (Dollars in thousands): $59,200 Amount subject to swaps: > Average rate to be received | Year of Maturity > 2008 > (Dollars in thousands): 4.8% Amount subject to swaps: > Average rate to be paid | Year of Maturity > 2008 > (Dollars in thousands): 5.6% \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt index a403722..7e038e7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt @@ -1,4 +1,3 @@ -2009 2009 > Fourth Quarter | NYSE Common Stock > High: $26.89 2009 > Fourth Quarter | NYSE Common Stock > Low: $19.75 2009 > Fourth Quarter | OSE Common Stock(1) > High: 156.30 @@ -15,7 +14,6 @@ 2009 > First Quarter | NYSE Common Stock > Low: 5.50 2009 > First Quarter | OSE Common Stock(1) > High: 106.50 2009 > First Quarter | OSE Common Stock(1) > Low: 38.70 -2008 2008 > Fourth Quarter | NYSE Common Stock > High: $21.26 2008 > Fourth Quarter | NYSE Common Stock > Low: $6.64 2008 > Fourth Quarter | OSE Common Stock(1) > High: 133.50 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt index 6aa71a6..be6f958 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2015 Balance as of December 31, 2015 > Goodwill | Vascular North America > (Dollars in thousands): $485,986 Balance as of December 31, 2015 > Goodwill | Interventional North America > (Dollars in thousands): $84,615 Balance as of December 31, 2015 > Goodwill | Anesthesia North America > (Dollars in thousands): $225,653 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt index 4aa2452..bfe1a9c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt @@ -1,4 +1,3 @@ -Mainline CASM: Mainline CASM: > Aircraft fuel and related taxes | 2013 > (In cents): 4.94 Mainline CASM: > Aircraft fuel and related taxes | 2012 > (In cents): 5.05 Mainline CASM: > Aircraft fuel and related taxes | Percent Increase (Decrease): (2.2) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt index 86ad95c..5fe09af 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt @@ -1,4 +1,3 @@ -Mainline CASM: Mainline CASM: > Aircraft fuel and related taxes | 2012 > (In cents): 5.05 Mainline CASM: > Aircraft fuel and related taxes | 2011 > (In cents): 4.77 Mainline CASM: > Aircraft fuel and related taxes | Percent Increase (Decrease): 5.9 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt index 8522d39..5cd725e 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt @@ -1,5 +1,3 @@ -Components of net periodic benefit cost: -Defined benefit plans: Defined benefit plans: > Service cost | Pension Benefits > 2014: $3 Defined benefit plans: > Service cost | Pension Benefits > 2013: $3 Defined benefit plans: > Service cost | Pension Benefits > 2012: $341 @@ -30,7 +28,6 @@ Defined benefit plans: > Settlements | Pension Benefits > 2012: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2014: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2013: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2012: — -Amortization of: Amortization of: > Prior service cost (1) | Pension Benefits > 2014: 28 Amortization of: > Prior service cost (1) | Pension Benefits > 2013: 28 Amortization of: > Prior service cost (1) | Pension Benefits > 2012: 10 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt index 107c426..44d2536 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt @@ -1,4 +1,3 @@ -Defined benefit plans: Defined benefit plans: > Service cost | Pension Benefits > 2015: $2 Defined benefit plans: > Service cost | Pension Benefits > 2014: $3 Defined benefit plans: > Service cost | Pension Benefits > 2013: $3 @@ -29,7 +28,6 @@ Defined benefit plans: > Settlements | Pension Benefits > 2013: (1) Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2015: — Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2014: — Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2013: — -Amortization of: Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2015: 28 Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2014: 28 Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2013: 28 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt index 424bbf3..7ae5765 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt @@ -1,4 +1,3 @@ -Fixed rate debt: Fixed rate debt: > Senior notes | Interest Rate: 2.65% to 7.50% Fixed rate debt: > Senior notes | Maturities Through: 2020 - 2028 Fixed rate debt: > Senior notes | As of December 31, > 2018: $1,724,194 @@ -13,7 +12,6 @@ Fixed rate debt: > Unsecured term loans | As of December 31, > 2018: 2,148,351 Fixed rate debt: > Unsecured term loans | As of December 31, > 2017: 333,351 Fixed rate debt: > Total fixed rate debt | As of December 31, > 2018: 4,542,982 Fixed rate debt: > Total fixed rate debt | As of December 31, > 2017: 2,199,710 -Variable rate debt (1) : Variable rate debt (1) : > Unsecured revolving credit facilities (2) | Interest Rate: 3.54% to 3.61% Variable rate debt (1) : > Unsecured revolving credit facilities (2) | Maturities Through: 2020 - 2022 Variable rate debt (1) : > Unsecured revolving credit facilities (2) | As of December 31, > 2018: 795,000 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt index ed25303..0a05b36 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt @@ -2,7 +2,6 @@ (dollars in millions) | Years Ended December 31, > 2015: Percentageof Total Net Sales (dollars in millions) | Years Ended December 31, > 2014: Net Sales (dollars in millions) | Years Ended December 31, > 2014: Percentageof Total Net Sales -Corporate: Corporate: > Medium/Large | Years Ended December 31, > 2015: $5,758.2 Corporate: > Medium/Large | Years Ended December 31, > 2015: 44.3% Corporate: > Medium/Large | Years Ended December 31, > 2014: $5,485.4 @@ -15,7 +14,6 @@ Corporate: > Total Corporate | Years Ended December 31, > 2015: 6,816.4 Corporate: > Total Corporate | Years Ended December 31, > 2015: 52.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 6,475.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 53.6 -Public: Public: > Government | Years Ended December 31, > 2015: 1,675.9 Public: > Government | Years Ended December 31, > 2015: 12.9 Public: > Government | Years Ended December 31, > 2014: 1,449.4 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt index ad77799..b9989fc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate | Years Ended December 31, > 2014 > Dollars inMillions: $439.8 Segments: (1) > Corporate | Years Ended December 31, > 2014 > OperatingMargin: 6.8% Segments: (1) > Corporate | Years Ended December 31, > 2013 > Dollars inMillions: $363.3 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt index ece3527..108d4b5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate | Years Ended December 31, > 2015 > Dollars inMillions: $470.1 Segments: (1) > Corporate | Years Ended December 31, > 2015 > OperatingMargin: 6.9% Segments: (1) > Corporate | Years Ended December 31, > 2014 > Dollars inMillions: $439.8 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt index 992342f..6adffa1 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt @@ -2,7 +2,6 @@ (dollars in millions) | Years Ended December 31, > 2014: Percentageof Total Net sales (dollars in millions) | Years Ended December 31, > 2013: Net Sales (dollars in millions) | Years Ended December 31, > 2013: Percentageof Total Net Sales -Corporate: Corporate: > Medium / Large | Years Ended December 31, > 2014: $5,485.4 Corporate: > Medium / Large | Years Ended December 31, > 2014: 45.4% Corporate: > Medium / Large | Years Ended December 31, > 2013: $5,052.7 @@ -15,7 +14,6 @@ Corporate: > Total Corporate | Years Ended December 31, > 2014: 6,475.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 53.6 Corporate: > Total Corporate | Years Ended December 31, > 2013: 5,960.1 Corporate: > Total Corporate | Years Ended December 31, > 2013: 55.3 -Public: Public: > Government | Years Ended December 31, > 2014: 1,449.4 Public: > Government | Years Ended December 31, > 2014: 12.0 Public: > Government | Years Ended December 31, > 2013: 1,250.6 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt index 8045437..5cc3035 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2016 > Dollars inMillions: $453.6 Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2016 > OperatingMargin: 7.7% Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2015 > Dollars inMillions: $432.5 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt index 5bb8622..73501b6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate (2) | Years Ended December 31, > 2017 > Dollars inMillions: $487.0 Segments: (1) > Corporate (2) | Years Ended December 31, > 2017 > OperatingMargin: 7.7% Segments: (1) > Corporate (2) | Years Ended December 31, > 2016 > Dollars inMillions: $453.6 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt index d60398d..965d940 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt @@ -1,4 +1,3 @@ -2011 2011 > Fourth Quarter | NYSE Common Stock > High: $30.99 2011 > Fourth Quarter | NYSE Common Stock > Low: $18.70 2011 > Fourth Quarter | OSE Common Stock (1) > High: 168.00 @@ -15,7 +14,6 @@ 2011 > First Quarter | NYSE Common Stock > Low: 40.26 2011 > First Quarter | OSE Common Stock (1) > High: 293.10 2011 > First Quarter | OSE Common Stock (1) > Low: 226.30 -2010 2010 > Fourth Quarter | NYSE Common Stock > High: $47.83 2010 > Fourth Quarter | NYSE Common Stock > Low: $30.87 2010 > Fourth Quarter | OSE Common Stock (1) > High: 284.70 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt index a97414e..e9eb698 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt @@ -1,4 +1,3 @@ -Composite Luxury (2) Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > 2008: 69.2% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: -1.9% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: pts. @@ -13,7 +12,6 @@ Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > 200 Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > Change vs. 2007: -0.1% Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > 2008: $225.87 Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > Change vs. 2007: -0.1% -Total Worldwide (3) Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > 2008: 70.4% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: -2.3% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: pts. diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt index 2d62039..f59a8a5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt @@ -1,4 +1,3 @@ -Composite Luxury (2) Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > 2010: 66.1% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: 5.9% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: pts. @@ -13,7 +12,6 @@ Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > 201 Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > Change vs. 2009: 10.2% Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > 2010: $193.17 Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > Change vs. 2009: 10.2% -Total Worldwide (3) Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > 2010: 68.7% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: 4.1% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: pts. diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt index f143505..6f3f9e3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt @@ -1,4 +1,3 @@ -Derivatives designated as hedging contracts Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Balance sheet location: Other current assets/(Other current liabilities) Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Asset derivatives December 31, > 2014 > Fair value: $309 Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Asset derivatives December 31, > 2013 > Fair value: $18 @@ -31,7 +30,6 @@ Derivatives designated as hedging contracts > Total | Asset derivatives December Derivatives designated as hedging contracts > Total | Asset derivatives December 31, > 2013 > Fair value: 335 Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2014 > Fair value: (87) Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2013 > Fair value: (179) -Derivatives not designated as hedging contracts Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Balance sheet location: Other current assets/(Other current liabilities) Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Asset derivatives December 31, > 2014 > Fair value: 73 Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Asset derivatives December 31, > 2013 > Fair value: 4 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt index fe359fb..cca08be 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt @@ -4,7 +4,6 @@ (Millions of dollars) | Non-U.S.Pension Benefits: 2016 (Millions of dollars) | Other PostretirementBenefits: 2017 (Millions of dollars) | Other PostretirementBenefits: 2016 -Change in benefit obligation: Change in benefit obligation: > Benefit obligation, beginning of year | U.S. Pension Benefits: $16,218 Change in benefit obligation: > Benefit obligation, beginning of year | U.S. Pension Benefits: $15,792 Change in benefit obligation: > Benefit obligation, beginning of year | Non-U.S.Pension Benefits: $4,472 @@ -75,7 +74,6 @@ Change in benefit obligation: > Accumulated benefit obligation, end of year | U. Change in benefit obligation: > Accumulated benefit obligation, end of year | U.S. Pension Benefits: $16,034 Change in benefit obligation: > Accumulated benefit obligation, end of year | Non-U.S.Pension Benefits: $4,335 Change in benefit obligation: > Accumulated benefit obligation, end of year | Non-U.S.Pension Benefits: $4,163 -Weighted-average assumptions used todetermine benefit obligation: Weighted-average assumptions used todetermine benefit obligation: > Discount rate | U.S. Pension Benefits: 3.5% Weighted-average assumptions used todetermine benefit obligation: > Discount rate | U.S. Pension Benefits: 4.0% Weighted-average assumptions used todetermine benefit obligation: > Discount rate | Non-U.S.Pension Benefits: 2.4% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt index 051051d..9f0bfc6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt @@ -1,4 +1,3 @@ -Derivatives designated as hedging contracts Derivatives designated as hedging contracts > Energy commodity derivative contracts | Balance sheetlocation: Current Derivatives designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2010 > Fair value: $20.1 Derivatives designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2009 > Fair value: $19.1 @@ -27,7 +26,6 @@ Derivatives designated as hedging contracts > Total | Asset derivatives December Derivatives designated as hedging contracts > Total | Asset derivatives December 31, > 2009 > Fair value: 312.4 Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2010 > Fair value: (448.1) Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2009 > Fair value: (740.4) -Derivatives not designated as hedging contracts Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Balance sheetlocation: Current Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2010 > Fair value: 3.9 Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2009 > Fair value: 1.7 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt index 2776eec..b9fd11b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt @@ -29,7 +29,4 @@ Per share goodwill impairment 4 | Twelve Months Ended December 31, > 2016: $0.98 Adjusted profit per share | Three Months Ended December 31, > 2017: $2.16 Adjusted profit per share | Three Months Ended December 31, > 2016: $0.83 Adjusted profit per share | Twelve Months Ended December 31, > 2017: $6.88 -Adjusted profit per share | Twelve Months Ended December 31, > 2016: $3.42 -2 At statutory tax rates prior to consideration of U.S. tax reform. -3 Net of U.S. federal tax at 35 percent. -4 Includes a $17 million tax benefit. \ No newline at end of file +Adjusted profit per share | Twelve Months Ended December 31, > 2016: $3.42 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt index 8c1343c..d6f86f9 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt @@ -4,7 +4,6 @@ (Millions of dollars) | Non-U.S.Pension Benefits: 2016 (Millions of dollars) | Other PostretirementBenefits: 2017 (Millions of dollars) | Other PostretirementBenefits: 2016 -Change in plan assets: Change in plan assets: > Fair value of plan assets, beginning of year | U.S. Pension Benefits: $11,354 Change in plan assets: > Fair value of plan assets, beginning of year | U.S. Pension Benefits: $11,440 Change in plan assets: > Fair value of plan assets, beginning of year | Non-U.S.Pension Benefits: $3,887 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt index d8ef7fb..94243da 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt @@ -7,7 +7,6 @@ (Millions of dollars) | Other Postretirement Benefits: 2017 (Millions of dollars) | Other Postretirement Benefits: 2016 (Millions of dollars) | Other Postretirement Benefits: 2015 -Components of net periodic benefit cost: Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $115 Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $119 Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $181 @@ -71,7 +70,6 @@ Components of net periodic benefit cost: > Total cost (benefit) included in oper Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $163 Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $160 Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $(362) -Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— @@ -108,7 +106,6 @@ Other changes in plan assets and benefit obligations recognized in other compreh Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $109 Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $35 Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $(292) -Weighted-average assumptions used to determine net cost: Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 4.2% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 4.5% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 3.8% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt index b607eed..9a5e79a 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt @@ -1,4 +1,3 @@ -Weighted-average assumptions used to determine benefit obligations, end of year: Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2018: 4.2% Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2017: 3.5% Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2016: 4.0% @@ -17,7 +16,6 @@ Weighted-average assumptions used to determine benefit obligations, end of year: Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2018: 4.0% Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2017: 4.0% Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2016: 4.0% -Weighted-average assumptions used to determine net cost: Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2018: 3.7% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2017: 4.2% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2016: 4.5% @@ -54,7 +52,6 @@ Weighted-average assumptions used to determine net cost: > Rate of compensation Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2018: 4.0% Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2017: 4.0% Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2016: 4.0% -Health care cost trend rates at year-end: Health care trend rate assumed for next year | Other Postretirement Benefits > 2018: 6.1% Health care trend rate assumed for next year | Other Postretirement Benefits > 2017: 6.1% Health care trend rate assumed for next year | Other Postretirement Benefits > 2016: 6.6% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt index af7a0dc..07c8677 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt @@ -1,4 +1,3 @@ -2006 2006 > Rental income (1) | First Quarter > (In thousands, except per share data): $104,964 2006 > Rental income (1) | Second Quarter > (In thousands, except per share data): $105,533 2006 > Rental income (1) | Third Quarter > (In thousands, except per share data): $110,511 @@ -19,7 +18,6 @@ 2006 > Earnings per common share — diluted | Second Quarter > (In thousands, except per share data): $0.66 2006 > Earnings per common share — diluted | Third Quarter > (In thousands, except per share data): $0.41 2006 > Earnings per common share — diluted | Fourth Quarter > (In thousands, except per share data): $0.32 -2005 2005 > Rental income (1) | First Quarter > (In thousands, except per share data): $97,783 2005 > Rental income (1) | Second Quarter > (In thousands, except per share data): $95,762 2005 > Rental income (1) | Third Quarter > (In thousands, except per share data): $96,772 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt index 27bb5fb..85f6d34 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt @@ -1,4 +1,3 @@ -East East > Rental income | 2006 > (Dollars in thousands): $340,968 East > Rental income | 2005 > (Dollars in thousands): $310,063 East > Rental income | 2004 > (Dollars in thousands): $293,291 @@ -17,7 +16,6 @@ East > Total assets | 2004 > (Dollars in thousands): $1,264,135 East > Gross leasable square feet | 2006 > (Dollars in thousands): 16,195 East > Gross leasable square feet | 2005 > (Dollars in thousands): 14,941 East > Gross leasable square feet | 2004 > (Dollars in thousands): 14,482 -West West > Rental income | 2006 > (Dollars in thousands): $97,233 West > Rental income | 2005 > (Dollars in thousands): $83,485 West > Rental income | 2004 > (Dollars in thousands): $75,008 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt index 172759c..9807829 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt @@ -1,4 +1,3 @@ -SUPPLEMENTAL DISCLOSURES: SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2007 > (In thousands): $125,259 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2006 > (In thousands): $106,877 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2005 > (In thousands): $94,257 @@ -17,7 +16,6 @@ SUPPLEMENTAL DISCLOSURES: > Cash paid for interest, net of amounts capitalized | SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2007 > (In thousands): $1,126 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2006 > (In thousands): $5,098(1) SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2005 > (In thousands): $82 -NON-CASH INVESTING AND FINANCING TRANSACTIONS: NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2007 > (In thousands): $79,987 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2006 > (In thousands): $44,297 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2005 > (In thousands): $22,258 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt index 198ef85..e666a53 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt @@ -1,4 +1,3 @@ -East East > Rental income | 2007 > (Dollars and square feet in thousands): $363,698 East > Rental income | 2006 > (Dollars and square feet in thousands): $318,176 East > Rental income | 2005 > (Dollars and square feet in thousands): $292,688 @@ -14,7 +13,6 @@ East > Property operating income as a percent of total revenue | 2005 > (Dollars East > Gross leasable square feet | 2007 > (Dollars and square feet in thousands): 15,568 East > Gross leasable square feet | 2006 > (Dollars and square feet in thousands): 16,195 East > Gross leasable square feet | 2005 > (Dollars and square feet in thousands): 14,941 -West West > Rental income | 2007 > (Dollars and square feet in thousands): $104,800 West > Rental income | 2006 > (Dollars and square feet in thousands): $96,803 West > Rental income | 2005 > (Dollars and square feet in thousands): $83,239 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt index 65e0a15..24c146d 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt @@ -1,4 +1,3 @@ -2009 2009 > Revenue(1) | First Quarter > (In thousands, except per share data): $131,076 2009 > Revenue(1) | Second Quarter > (In thousands, except per share data): $130,338 2009 > Revenue(1) | Third Quarter > (In thousands, except per share data): $130,992 @@ -27,7 +26,6 @@ 2009 > Earnings per common share—diluted | Second Quarter > (In thousands, except per share data): $0.48 2009 > Earnings per common share—diluted | Third Quarter > (In thousands, except per share data): $0.45 2009 > Earnings per common share—diluted | Fourth Quarter > (In thousands, except per share data): $0.52 -2008 2008 > Revenue(1) | First Quarter > (In thousands, except per share data): $126,242 2008 > Revenue(1) | Second Quarter > (In thousands, except per share data): $128,712 2008 > Revenue(1) | Third Quarter > (In thousands, except per share data): $131,707 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt index 2e9b8b2..b030ff8 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt @@ -1,4 +1,3 @@ -2010 2010 > Revenue(1) | First Quarter > (In thousands, except per share data): $138,324 2010 > Revenue(1) | Second Quarter > (In thousands, except per share data): $133,689 2010 > Revenue(1) | Third Quarter > (In thousands, except per share data): $133,913 @@ -27,7 +26,6 @@ 2010 > Earnings per common share—diluted(2) | Second Quarter > (In thousands, except per share data): $0.50 2010 > Earnings per common share—diluted(2) | Third Quarter > (In thousands, except per share data): $0.48 2010 > Earnings per common share—diluted(2) | Fourth Quarter > (In thousands, except per share data): $0.53 -2009 2009 > Revenue(1) | First Quarter > (In thousands, except per share data): $131,031 2009 > Revenue(1) | Second Quarter > (In thousands, except per share data): $130,225 2009 > Revenue(1) | Third Quarter > (In thousands, except per share data): $130,841 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt index 1347a29..02e609b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt @@ -1,4 +1,3 @@ -SUPPLEMENTAL DISCLOSURES: SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2010 > (In thousands): $108,167 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2009 > (In thousands): $114,330 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2008 > (In thousands): $104,464 @@ -14,7 +13,6 @@ SUPPLEMENTAL DISCLOSURES: > Cash paid for interest, net of amounts capitalized | SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2010 > (In thousands): $255 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2009 > (In thousands): $324 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2008 > (In thousands): $444 -NON-CASH INVESTING AND FINANCING TRANSACTIONS: NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2010 > (In thousands): $8,832 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2009 > (In thousands): $— NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2008 > (In thousands): $— diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt index df6186a..c1e6efc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt @@ -1,4 +1,3 @@ -2005 2005 > Rental income (1) | First Quarter > (In thousands, except per share data): $98,306 2005 > Rental income (1) | Second Quarter > (In thousands, except per share data): $96,175 2005 > Rental income (1) | Third Quarter > (In thousands, except per share data): $97,233 @@ -19,7 +18,6 @@ 2005 > Earnings per common share — diluted | Second Quarter > (In thousands, except per share data): $0.41 2005 > Earnings per common share — diluted | Third Quarter > (In thousands, except per share data): $0.52 2005 > Earnings per common share — diluted | Fourth Quarter > (In thousands, except per share data): $0.61 -2004 2004 > Rental income (1) | First Quarter > (In thousands, except per share data): $89,388 2004 > Rental income (1) | Second Quarter > (In thousands, except per share data): $93,243 2004 > Rental income (1) | Third Quarter > (In thousands, except per share data): $93,459 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt index b588ab4..c5060c3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt @@ -7,7 +7,6 @@ Beginning cash and cash equivalents | One Year Change > $: $(112,818) Beginning cash and cash equivalents | One Year Change > %: -24% Beginning cash and cash equivalents | Two Year Change > $: $202,128 Beginning cash and cash equivalents | Two Year Change > %: 127% -Cash provided from (used in): Cash provided from (used in): > Operating activities | Year Ended > December 31, 2014: 1,138,670 Cash provided from (used in): > Operating activities | Year Ended > December 31, 2015: 1,373,468 Cash provided from (used in): > Operating activities | One Year Change > $: 234,798 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt index dfbe828..fd22d1b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2005 | Treasury > Stock: $(199,482) Balance at October 31, 2005 | Deferred > Stock > Compensation: $(1,475) Balance at October 31, 2005 | Accumulated Other > Comprehensive > Income (Loss): $(16,001) Balance at October 31, 2005 | Total: $1,210,637 -Components of comprehensive income: Components of comprehensive income: > Net income | Retained > Earnings: 24,742 Components of comprehensive income: > Net income | Accumulated Other > Comprehensive > Income (Loss): 24,742 Components of comprehensive income: > Net income | Total: 24,742 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt index 3a2b551..50ed47b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2004 | Treasury > Stock: $(175,762) Balance at October 31, 2004 | Deferred > Stock > Compensation: $(2,732) Balance at October 31, 2004 | Accumulated Other > Comprehensive > Income (Loss): $(645) Balance at October 31, 2004 | Total: $1,258,455 -Components of comprehensive loss Components of comprehensive loss > Net loss | Retained > Earnings: (17,114) Components of comprehensive loss > Net loss | Accumulated Other > Comprehensive > Income (Loss): (17,114) Components of comprehensive loss > Net loss | Total: (17,114) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt index 7d6a857..47b8ac7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2003 | Treasury > Stock: $(20,733) Balance at October 31, 2003 | Deferred > Stock > Compensation: $(7,170) Balance at October 31, 2003 | Accumulated Other > Comprehensive > Income (Loss): $9,353 Balance at October 31, 2003 | Total: $1,426,069 -Components of comprehensive income: Components of comprehensive income: > Net income | Retained > Earnings: 75,084 Components of comprehensive income: > Net income | Accumulated Other > Comprehensive > Income (Loss): 75,084 Components of comprehensive income: > Net income | Total: 75,084 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt index f86ee4b..4c2b611 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt @@ -1,5 +1,3 @@ -Balance at October 31, 2009 -Classified as current assets: Classified as current assets: > Non-interest bearing cash (U.S. and International) | Cost > (in thousands): $40,390 Classified as current assets: > Non-interest bearing cash (U.S. and International) | Gross Unrealized Gains > (in thousands): $— Classified as current assets: > Non-interest bearing cash (U.S. and International) | Gross Unrealized Losses Less Than 12 Months > (in thousands): $— @@ -25,7 +23,6 @@ Gross Unrealized Gains > (in thousands): 2,827 Gross Unrealized Losses Less Than 12 Months > (in thousands): (80) Gross Unrealized Losses 12 Months or Longer > (in thousands): — Estimated Fair Value > (in thousands): 1,168,326 -Classified as non-current assets: Classified as non-current assets: > Strategic investments | Cost > (in thousands): 8,002 Classified as non-current assets: > Strategic investments | Gross Unrealized Gains > (in thousands): 1,796 Classified as non-current assets: > Strategic investments | Gross Unrealized Losses Less Than 12 Months > (in thousands): — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt index b888b28..802ed26 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2003 | Treasury > Stock: $(20,733) Balance at October 31, 2003 | Deferred > Stock > Compensation: $(7,170) Balance at October 31, 2003 | Accumulated Other > Comprehensive > Income (Loss): $9,353 Balance at October 31, 2003 | Total: $1,433,410 -Components of comprehensive income: Components of comprehensive income: > Net income | Common Stock > Shares: — Components of comprehensive income: > Net income | Common Stock > Amount: — Components of comprehensive income: > Net income | Capital in Excess > of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt index eb49406..d3fc767 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2002 | Treasury > Stock: $(116,499) Balance at October 31, 2002 | Deferred Stock > Compensation: $(8,858) Balance at October 31, 2002 | Accumulated Other Comprehensive > Income (Loss): $(146) Balance at October 31, 2002 | Total: $1,113,481 -Components of comprehensive income: Components of comprehensive income: > Net income | Common Stock > Shares: — Components of comprehensive income: > Net income | Common Stock > Amount: — Components of comprehensive income: > Net income | Capital in Excess of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt index ff02a91..a2ef4f8 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2004 | Treasury > Stock: $(175,762) Balance at October 31, 2004 | Deferred > Stock > Compensation: $(2,732) Balance at October 31, 2004 | Accumulated Other > Comprehensive > Income (Loss): $(645) Balance at October 31, 2004 | Total: $1,265,049 -Components of comprehensive income: Components of comprehensive income: > Net loss | Common Stock > Shares: — Components of comprehensive income: > Net loss | Common Stock > Amount: — Components of comprehensive income: > Net loss | Capital in Excess > of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt index 2e7755a..cdfbc65 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt @@ -1,11 +1,9 @@ -Nonvested balance — Nonvested balance — > As of January 1 | 2013 > Number of Awards: 3,261,562 Nonvested balance — > As of January 1 | 2013 > Weighted Average Grant Date Fair Value: $85.17 Nonvested balance — > As of January 1 | 2012 > Number of Awards: 4,858,972 Nonvested balance — > As of January 1 | 2012 > Weighted Average Grant Date Fair Value: $73.02 Nonvested balance — > As of January 1 | 2011 > Number of Awards: 4,812,657 Nonvested balance — > As of January 1 | 2011 > Weighted Average Grant Date Fair Value: $68.75 -Granted Granted > Annual | 2013 > Number of Awards: 946,774 Granted > Annual | 2013 > Weighted Average Grant Date Fair Value: 101.57 Granted > Annual | 2012 > Number of Awards: 968,522 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt index a3588f4..a23f343 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt @@ -4,7 +4,6 @@ (Millions) | Qualified and Non-qualified Pension Benefits > International: 2014 (Millions) | Postretirement > Benefits: 2015 (Millions) | Postretirement > Benefits: 2014 -Amounts recognized in accumulated other comprehensive income as of Dec. 31, Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > United States: $— Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > United States: $— Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > International: $(2) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt index b0b97dc..9692f4b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt @@ -1,4 +1,3 @@ -Undistributed balance — Undistributed balance — > As of January 1 | 2015 > Number of Awards: 1,099,752 Undistributed balance — > As of January 1 | 2015 > Weighted Average Grant Date Fair Value: $102.65 Undistributed balance — > As of January 1 | 2014 > Number of Awards: 895,635 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt index 3576a9a..ad7d18a 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt @@ -1,11 +1,9 @@ -Nonvested balance — Nonvested balance — > As of January 1 | 2015 > Number of Awards: 2,817,786 Nonvested balance — > As of January 1 | 2015 > Weighted Average Grant Date Fair Value: $104.41 Nonvested balance — > As of January 1 | 2014 > Number of Awards: 3,105,361 Nonvested balance — > As of January 1 | 2014 > Weighted Average Grant Date Fair Value: $92.31 Nonvested balance — > As of January 1 | 2013 > Number of Awards: 3,261,562 Nonvested balance — > As of January 1 | 2013 > Weighted Average Grant Date Fair Value: $85.17 -Granted Granted > Annual | 2015 > Number of Awards: 671,204 Granted > Annual | 2015 > Weighted Average Grant Date Fair Value: 165.86 Granted > Annual | 2014 > Number of Awards: 798,615 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt index 0b1d6c8..89a9198 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt @@ -6,7 +6,6 @@ (Dollars in millions) | 2014 > Oper.: Income (Dollars in millions) | 2015 vs 2014 % change > Net: Sales (Dollars in millions) | 2015 vs 2014 % change > Oper.: Income -Business Segments Business Segments > Industrial | 2015 > Net: $10,328 Business Segments > Industrial | 2015 > % of: 34.1% Business Segments > Industrial | 2015 > Oper.: $2,263 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt index 4cefdf7..7951ca7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt @@ -1,11 +1,9 @@ -Under option — Under option — > January 1 | 2015 > Number of Options: 39,235,557 Under option — > January 1 | 2015 > Weighted Average Exercise Price: $90.38 Under option — > January 1 | 2014 > Number of Options: 43,938,778 Under option — > January 1 | 2014 > Weighted Average Exercise Price: $83.84 Under option — > January 1 | 2013 > Number of Options: 56,565,030 Under option — > January 1 | 2013 > Weighted Average Exercise Price: $80.33 -Granted: Granted: > Annual | 2015 > Number of Options: 5,529,544 Granted: > Annual | 2015 > Weighted Average Exercise Price: 165.91 Granted: > Annual | 2014 > Number of Options: 5,736,183 @@ -42,7 +40,6 @@ Granted: > December 31 | 2014 > Number of Options: 39,235,557 Granted: > December 31 | 2014 > Weighted Average Exercise Price: $90.38 Granted: > December 31 | 2013 > Number of Options: 43,938,778 Granted: > December 31 | 2013 > Weighted Average Exercise Price: $83.84 -Options exercisable Options exercisable > December 31 | 2015 > Number of Options: 27,262,062 Options exercisable > December 31 | 2015 > Weighted Average Exercise Price: $85.97 Options exercisable > December 31 | 2014 > Number of Options: 27,502,208 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt index 4510417..cedddc1 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt @@ -4,14 +4,12 @@ (Millions) | Qualified and Non-qualified Pension Benefits > International: 2014 (Millions) | Postretirement > Benefits: 2015 (Millions) | Postretirement > Benefits: 2014 -Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > United States: $3 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > United States: $3 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > International: $185 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > International: $43 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Postretirement > Benefits: $— Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Postretirement > Benefits: $— -Accrued benefit cost Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > United States: (47) Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > United States: (46) Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > International: (10) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt index b461782..d80bae5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt @@ -1,11 +1,9 @@ -Under option — Under option — > January 1 | 2012 > Number of Options: 64,148,415 Under option — > January 1 | 2012 > Weighted Average Exercise Price: $77.28 Under option — > January 1 | 2011 > Number of Options: 70,335,044 Under option — > January 1 | 2011 > Weighted Average Exercise Price: $74.80 Under option — > January 1 | 2010 > Number of Options: 74,268,165 Under option — > January 1 | 2010 > Weighted Average Exercise Price: $72.39 -Granted: Granted: > Annual | 2012 > Number of Options: 5,770,190 Granted: > Annual | 2012 > Weighted Average Exercise Price: 87.91 Granted: > Annual | 2011 > Number of Options: 5,514,500 @@ -42,7 +40,6 @@ Granted: > December 31 | 2011 > Number of Options: 64,148,415 Granted: > December 31 | 2011 > Weighted Average Exercise Price: $77.28 Granted: > December 31 | 2010 > Number of Options: 70,335,044 Granted: > December 31 | 2010 > Weighted Average Exercise Price: $74.80 -Options exercisable Options exercisable > December 31 | 2012 > Number of Options: 45,207,143 Options exercisable > December 31 | 2012 > Weighted Average Exercise Price: $78.78 Options exercisable > December 31 | 2011 > Number of Options: 52,644,364 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt index 7fc9466..6983d33 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt @@ -43,7 +43,6 @@ Same store NOI | One Year Change > Amount%: 19,953 Same store NOI | One Year Change: 1% Same store NOI | Two Year Change > Amount%: 41,590 Same store NOI | Two Year Change: 3% -Per share data (fully diluted): Per share data (fully diluted): > Net income attributable to common stockholders | Year Ended > December 31, 2014: $1.45 Per share data (fully diluted): > Net income attributable to common stockholders | Year Ended > December 31, 2015: $2.34 Per share data (fully diluted): > Net income attributable to common stockholders | One Year Change > Amount%: $0.89 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt index e139f94..4c57bac 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt @@ -1,4 +1,3 @@ -Foreign exchange instruments qualifying as accounting hedges: Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Notional Principal: $351 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Fair Value: $6 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Credit Risk Amounts: $6 @@ -17,7 +16,6 @@ Foreign exchange instruments qualifying as accounting hedges: > Sold options | S Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Notional Principal: $1,087 Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Fair Value: $(5) Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Creit Risk Amounts: $— -Foreign exchange instruments other than accounting hedges: Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Notional Principal: $1,103 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Fair Value: $2 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Credit Risk Amounts: $2 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt index 09344d2..96d1933 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt @@ -1,4 +1,3 @@ -2005 2005 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $3,678 2005 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $3,520 2005 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $3,243 @@ -11,7 +10,6 @@ 2005 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $320 2005 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $290 2005 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $295 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.52 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.39 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.36 @@ -20,7 +18,6 @@ Earnings per common share: > Diluted | Fourth Quarter > (Tabular amounts in mill Earnings per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.37 Earnings per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.34 Earnings per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $0.35 -2004 2004 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $2,350 2004 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $2,014 2004 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,909 @@ -33,7 +30,6 @@ Earnings per common share: > Diluted | First Quarter > (Tabular amounts in milli 2004 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $61 2004 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $46 2004 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $63 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.14 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.08 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.06 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt index 6cec04e..e771cfa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt @@ -1,4 +1,3 @@ -Foreign exchange instruments qualifying as accounting hedges: Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Notional Principal: $662 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Fair Value: $10 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Credit Risk Amounts: $10 @@ -17,7 +16,6 @@ Foreign exchange instruments qualifying as accounting hedges: > Sold options | S Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Notional Principal: $521 Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Fair Value: $(3) Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Credit Risk Amounts: $— -Foreign exchange instruments other than accounting hedges: Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Notional Principal: $833 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Fair Value: $(3) Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Credit Risk Amounts: $1 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt index 32ffe4a..8146e33 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt @@ -1,4 +1,3 @@ -2003 2003 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,715 2003 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,545 2003 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,475 @@ -11,7 +10,6 @@ 2003 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $19 2003 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $14 2003 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $(8) -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 @@ -20,7 +18,6 @@ Earnings (loss) per common share: > Diluted | Fourth Quarter > (Tabular amounts Earnings (loss) per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 Earnings (loss) per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $(0.02) -2002 2002 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,443 2002 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,429 2002 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,495 @@ -33,7 +30,6 @@ Earnings (loss) per common share: > Diluted | First Quarter > (Tabular amounts i 2002 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $32 2002 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $40 2002 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $38 -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $(0.13) Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.09 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.11 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt index 6d9733f..7a75b9d 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt @@ -1,4 +1,3 @@ -2004 2004 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $2,350 2004 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $2,014 2004 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,909 @@ -11,7 +10,6 @@ 2004 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $61 2004 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $46 2004 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $63 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.28 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.16 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.13 @@ -20,7 +18,6 @@ Earnings per common share: > Diluted | Fourth Quarter > (Tabular amounts in mill Earnings per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.16 Earnings per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $0.17 -2003 2003 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,715 2003 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,545 2003 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,475 @@ -33,7 +30,6 @@ Earnings per common share: > Diluted | First Quarter > (Tabular amounts in milli 2003 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $19 2003 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $14 2003 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $(8) -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt index 619c73a..4aa8588 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt @@ -1,4 +1,3 @@ -(in millions) (in millions) > Long-term debt (1) | Total: $27,922 (in millions) > Long-term debt (1) | Payments Due > 2016: $2,405 (in millions) > Long-term debt (1) | Payments Due > 2017-2018: $5,097 @@ -24,7 +23,6 @@ (in millions) > Operating leases (5) | Payments Due > 2017-2018: 207 (in millions) > Operating leases (5) | Payments Due > 2019-2020: 103 (in millions) > Operating leases (5) | Payments Due > 2021 andThereafter: 195 -Purchase obligations (6) : Purchase obligations (6) : > Inventory and production costs | Total: 5,094 Purchase obligations (6) : > Inventory and production costs | Payments Due > 2016: 2,007 Purchase obligations (6) : > Inventory and production costs | Payments Due > 2017-2018: 1,586 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt index 5bd9432..dd78511 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt @@ -14,7 +14,6 @@ Operating leases (3) > 849 | Payments Due: 179 Operating leases (3) > 849 | Payments Due: 219 Operating leases (3) > 849 | Payments Due: 95 Operating leases (3) > 849 | Payments Due: 356 -Purchase obligations (4) : Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 2,696 Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 1,255 Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 687 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt index 0bc4562..b5c0d70 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt @@ -14,7 +14,6 @@ Operating leases (3) > 772 | Payments Due: 147 Operating leases (3) > 772 | Payments Due: 176 Operating leases (3) > 772 | Payments Due: 95 Operating leases (3) > 772 | Payments Due: 354 -Purchase obligations (4) : Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 2,492 Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 1,165 Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 406 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt index 70bebcc..0fb11eb 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt @@ -1,4 +1,3 @@ -Period Ended: Period Ended: > Net sales (b)(d) | Successor > December 30,2017(52 weeks) > (in millions, except per share data): $26,232 Period Ended: > Net sales (b)(d) | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): $26,487 Period Ended: > Net sales (b)(d) | Successor > January 3,2016(53 weeks) > (in millions, except per share data): $18,338 @@ -20,7 +19,6 @@ Period Ended: > Income/(loss) from continuing operations attributable to common Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Successor > February 8 - December 29,2013(29 weeks) > (in millions, except per share data): (1,118) Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Predecessor(H. J. Heinz Company) > April 29 - June 7,2013(6 weeks) > (in millions, except per share data): (194) Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Predecessor(H. J. Heinz Company) > April 28,2013(52 weeks) > (in millions, except per share data): 1,088 -Income/(loss) from continuing operations per common share (b) : Income/(loss) from continuing operations per common share (b) : > Basic | Successor > December 30,2017(52 weeks) > (in millions, except per share data): 9.03 Income/(loss) from continuing operations per common share (b) : > Basic | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): 2.84 Income/(loss) from continuing operations per common share (b) : > Basic | Successor > January 3,2016(53 weeks) > (in millions, except per share data): (0.34) @@ -35,7 +33,6 @@ Income/(loss) from continuing operations per common share (b) : > Diluted | Succ Income/(loss) from continuing operations per common share (b) : > Diluted | Successor > February 8 - December 29,2013(29 weeks) > (in millions, except per share data): (2.97) Income/(loss) from continuing operations per common share (b) : > Diluted | Predecessor(H. J. Heinz Company) > April 29 - June 7,2013(6 weeks) > (in millions, except per share data): (0.60) Income/(loss) from continuing operations per common share (b) : > Diluted | Predecessor(H. J. Heinz Company) > April 28,2013(52 weeks) > (in millions, except per share data): 3.37 -As of: As of: > Total assets (d) | Successor > December 30,2017(52 weeks) > (in millions, except per share data): 120,232 As of: > Total assets (d) | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): 120,480 As of: > Total assets (d) | Successor > January 3,2016(53 weeks) > (in millions, except per share data): 122,973 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt index 932c73a..43b09ce 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt @@ -1,4 +1,3 @@ -2013 2013 > Fourth Quarter | NYSECommon Stock > High: $47.66 2013 > Fourth Quarter | NYSECommon Stock > Low: $35.97 2013 > Fourth Quarter | OSECommon Stock (1) > High: 292.60 @@ -15,7 +14,6 @@ 2013 > First Quarter | NYSECommon Stock > Low: 31.72 2013 > First Quarter | OSECommon Stock (1) > High: 213.50 2013 > First Quarter | OSECommon Stock (1) > Low: 184.10 -2012 2012 > Fourth Quarter | NYSECommon Stock > High: $36.18 2012 > Fourth Quarter | NYSECommon Stock > Low: $30.26 2012 > Fourth Quarter | OSECommon Stock (1) > High: 202.50 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt index cc2f9e6..cdfdd49 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt @@ -1,4 +1,3 @@ -2015 2015 > First Quarter | Class A > High: $60.70 2015 > First Quarter | Class A > Low: $52.45 2015 > First Quarter | Class A Special > High: $60.19 @@ -15,7 +14,6 @@ 2015 > FourthQuarter (a) | Class A > Low: $55.39 2015 > FourthQuarter (a) | Class A Special > High: $63.48 2015 > FourthQuarter (a) | Class A Special > Low: $56.88 -2014 2014 > First Quarter | Class A > High: $55.28 2014 > First Quarter | Class A > Low: $49.00 2014 > First Quarter | Class A Special > High: $53.10 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt index 4f9dbf1..158e850 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt @@ -22,7 +22,6 @@ Rate of compensation increase | Pension Plans > 2016: 2.94% Rate of compensation increase | Postretirement Benefit Plans > 2018: 3.25% Rate of compensation increase | Postretirement Benefit Plans > 2017: 3.25% Rate of compensation increase | Postretirement Benefit Plans > 2016: 3.25% -Health care cost trend Health care cost trend > Initial | Postretirement Benefit Plans > 2018: 6.50% Health care cost trend > Initial | Postretirement Benefit Plans > 2017: 6.75% Health care cost trend > Initial | Postretirement Benefit Plans > 2016: 7.00% @@ -83,7 +82,6 @@ Health care cost trend > Rate of compensation increase | Pension Plans > 2016: 3 Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2018: 3.25% Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2017: 3.25% Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2016: 3.50% -Health care cost trend Health care cost trend > Initial | Postretirement Benefit Plans > 2018: 6.75% Health care cost trend > Initial | Postretirement Benefit Plans > 2017: 7.00% Health care cost trend > Initial | Postretirement Benefit Plans > 2016: 7.50% diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt index cc9c5bf..e1ef663 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt @@ -1,42 +1,40 @@ -Hypertensives -Malay | Male > M: 28 -Malay | Male > T: 14 -Malay | Female > M: 36 -Malay | Female > T: 26 -Chinese | Male > M: 10 -Chinese | Male > T: 10 -Chinese | Female > M: 28 -Chinese | Female > T: 20 -Indian | Male > M: 1 -Indian | Male > T: 3 -Indian | Female > M: 9 -Indian | Female > T: 17 -Total | Male > M: 39 -Total | Male > T: 27 -Total | Female > M: 73 -Total | Female > T: 63 -Normotensives -Malay | Male > M: 25 -Malay | Male > T: 5 -Malay | Female > M: 48 -Malay | Female > T: 12 -Chinese | Male > M: 4 -Chinese | Male > T: 4 -Chinese | Female > M: 28 -Chinese | Female > T: 8 -Indian | Male > M: 7 -Indian | Male > T: 1 -Indian | Female > M: 24 -Indian | Female > T: 8 -Total | Male > M: 36 -Total | Male > T: 10 -Total | Female > M: 100 -Total | Female > T: 28 -χ 2 value | Male > M: 3.836 -χ 2 value | Male > T: 3.836 -χ 2 value | Female > M: 20.828 -χ 2 value | Female > T: 20.828 -P * value | Male > M: 0.140 -P * value | Male > T: 0.140 -P * value | Female > M: 0.001 -P * value | Female > T: 0.001 \ No newline at end of file +Hypertensives > Malay | Male > M: 28 +Hypertensives > Malay | Male > T: 14 +Hypertensives > Malay | Female > M: 36 +Hypertensives > Malay | Female > T: 26 +Hypertensives > Chinese | Male > M: 10 +Hypertensives > Chinese | Male > T: 10 +Hypertensives > Chinese | Female > M: 28 +Hypertensives > Chinese | Female > T: 20 +Hypertensives > Indian | Male > M: 1 +Hypertensives > Indian | Male > T: 3 +Hypertensives > Indian | Female > M: 9 +Hypertensives > Indian | Female > T: 17 +Hypertensives > Total | Male > M: 39 +Hypertensives > Total | Male > T: 27 +Hypertensives > Total | Female > M: 73 +Hypertensives > Total | Female > T: 63 +Normotensives > Malay | Male > M: 25 +Normotensives > Malay | Male > T: 5 +Normotensives > Malay | Female > M: 48 +Normotensives > Malay | Female > T: 12 +Normotensives > Chinese | Male > M: 4 +Normotensives > Chinese | Male > T: 4 +Normotensives > Chinese | Female > M: 28 +Normotensives > Chinese | Female > T: 8 +Normotensives > Indian | Male > M: 7 +Normotensives > Indian | Male > T: 1 +Normotensives > Indian | Female > M: 24 +Normotensives > Indian | Female > T: 8 +Normotensives > Total | Male > M: 36 +Normotensives > Total | Male > T: 10 +Normotensives > Total | Female > M: 100 +Normotensives > Total | Female > T: 28 +Normotensives > χ 2 value | Male > M: 3.836 +Normotensives > χ 2 value | Male > T: 3.836 +Normotensives > χ 2 value | Female > M: 20.828 +Normotensives > χ 2 value | Female > T: 20.828 +Normotensives > P * value | Male > M: 0.140 +Normotensives > P * value | Male > T: 0.140 +Normotensives > P * value | Female > M: 0.001 +Normotensives > P * value | Female > T: 0.001 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt index ded67d5..17952ba 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt @@ -4,48 +4,47 @@ Number Graduated | Decompressed > Raw: 37 Number Graduated | %: 58.7 Number Graduated | Repeated > Raw: 12 Number Graduated | %: 27.2 -For those who completed: -Five Years to Graduate | Decompressed > Raw: 29 -Five Years to Graduate | %: 46 -Five Years to Graduate | Repeated > Raw: 8 -Five Years to Graduate | %: 18 -Six Years to Graduate | Decompressed > Raw: 4 -Six Years to Graduate | %: 6 -Six Years to Graduate | Repeated > Raw: 3 -Six Years to Graduate | %: 7 -Seven Years to Graduate | Decompressed > Raw: 3 -Seven Years to Graduate | %: 5 -Seven Years to Graduate | Repeated > Raw: 0 -Seven Years to Graduate | %: 0 -Eight Years to Graduate | Decompressed > Raw: 1 -Eight Years to Graduate | %: 2 -Eight Years to Graduate | Repeated > Raw: 0 -Eight Years to Graduate | %: 0 -Twelve Years to Graduate | Decompressed > Raw: 0 -Twelve Years to Graduate | %: 0 -Twelve Years to Graduate | Repeated > Raw: 1 -Twelve Years to Graduate | %: 2 -1 Attempt to Pass Step 1 | Decompressed > Raw: 29 -1 Attempt to Pass Step 1 | %: 46 -1 Attempt to Pass Step 1 | Repeated > Raw: 7 -1 Attempt to Pass Step 1 | %: 15.9 -2 Attempts to Pass Step 1 | Decompressed > Raw: 7 -2 Attempts to Pass Step 1 | %: 11 -2 Attempts to Pass Step 1 | Repeated > Raw: 1 -2 Attempts to Pass Step 1 | %: 2 -3 Attempts to Pass Step 1 | Decompressed > Raw: 1 -3 Attempts to Pass Step 1 | %: 2 -3 Attempts to Pass Step 1 | Repeated > Raw: 4 -3 Attempts to Pass Step 1 | %: 9 -1 Attempt to Pass Step 2 | Decompressed > Raw: 32 -1 Attempt to Pass Step 2 | %: 50.8 -1 Attempt to Pass Step 2 | Repeated > Raw: 9 -1 Attempt to Pass Step 2 | %: 20.5 -2 Attempts to Pass Step 2 | Decompressed > Raw: 3 -2 Attempts to Pass Step 2 | %: 4.8 -2 Attempts to Pass Step 2 | Repeated > Raw: 2 -2 Attempts to Pass Step 2 | %: 4.5 -3 Attempts to Pass Step 2 | Decompressed > Raw: 2 -3 Attempts to Pass Step 2 | %: 3 -3 Attempts to Pass Step 2 | Repeated > Raw: 1 -3 Attempts to Pass Step 2 | %: 2.3 \ No newline at end of file +For those who completed: > Five Years to Graduate | Decompressed > Raw: 29 +For those who completed: > Five Years to Graduate | %: 46 +For those who completed: > Five Years to Graduate | Repeated > Raw: 8 +For those who completed: > Five Years to Graduate | %: 18 +For those who completed: > Six Years to Graduate | Decompressed > Raw: 4 +For those who completed: > Six Years to Graduate | %: 6 +For those who completed: > Six Years to Graduate | Repeated > Raw: 3 +For those who completed: > Six Years to Graduate | %: 7 +For those who completed: > Seven Years to Graduate | Decompressed > Raw: 3 +For those who completed: > Seven Years to Graduate | %: 5 +For those who completed: > Seven Years to Graduate | Repeated > Raw: 0 +For those who completed: > Seven Years to Graduate | %: 0 +For those who completed: > Eight Years to Graduate | Decompressed > Raw: 1 +For those who completed: > Eight Years to Graduate | %: 2 +For those who completed: > Eight Years to Graduate | Repeated > Raw: 0 +For those who completed: > Eight Years to Graduate | %: 0 +For those who completed: > Twelve Years to Graduate | Decompressed > Raw: 0 +For those who completed: > Twelve Years to Graduate | %: 0 +For those who completed: > Twelve Years to Graduate | Repeated > Raw: 1 +For those who completed: > Twelve Years to Graduate | %: 2 +For those who completed: > 1 Attempt to Pass Step 1 | Decompressed > Raw: 29 +For those who completed: > 1 Attempt to Pass Step 1 | %: 46 +For those who completed: > 1 Attempt to Pass Step 1 | Repeated > Raw: 7 +For those who completed: > 1 Attempt to Pass Step 1 | %: 15.9 +For those who completed: > 2 Attempts to Pass Step 1 | Decompressed > Raw: 7 +For those who completed: > 2 Attempts to Pass Step 1 | %: 11 +For those who completed: > 2 Attempts to Pass Step 1 | Repeated > Raw: 1 +For those who completed: > 2 Attempts to Pass Step 1 | %: 2 +For those who completed: > 3 Attempts to Pass Step 1 | Decompressed > Raw: 1 +For those who completed: > 3 Attempts to Pass Step 1 | %: 2 +For those who completed: > 3 Attempts to Pass Step 1 | Repeated > Raw: 4 +For those who completed: > 3 Attempts to Pass Step 1 | %: 9 +For those who completed: > 1 Attempt to Pass Step 2 | Decompressed > Raw: 32 +For those who completed: > 1 Attempt to Pass Step 2 | %: 50.8 +For those who completed: > 1 Attempt to Pass Step 2 | Repeated > Raw: 9 +For those who completed: > 1 Attempt to Pass Step 2 | %: 20.5 +For those who completed: > 2 Attempts to Pass Step 2 | Decompressed > Raw: 3 +For those who completed: > 2 Attempts to Pass Step 2 | %: 4.8 +For those who completed: > 2 Attempts to Pass Step 2 | Repeated > Raw: 2 +For those who completed: > 2 Attempts to Pass Step 2 | %: 4.5 +For those who completed: > 3 Attempts to Pass Step 2 | Decompressed > Raw: 2 +For those who completed: > 3 Attempts to Pass Step 2 | %: 3 +For those who completed: > 3 Attempts to Pass Step 2 | Repeated > Raw: 1 +For those who completed: > 3 Attempts to Pass Step 2 | %: 2.3 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt index 57aeaed..9d71c76 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt @@ -1,42 +1,40 @@ -Survivin levels (pg/ml) -Blood | Survivin high, erosive RA ( n = 27): 1180 ± 309 -Blood | P: <0.0001 -Blood | Survivin low, erosive RA ( n = 61): 97 ± 9 -Blood | P: 0.013 -Blood | Survivin low, non-erosive RA ( n = 42) †: 127 ± 5 -Synovial fluid | Survivin high, erosive RA ( n = 27): 1039 ± 523 -Synovial fluid | P: 0.016 -Synovial fluid | Survivin low, erosive RA ( n = 61): 132 ± 4 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 124 ± 2 -Disease duration (years) | Survivin high, erosive RA ( n = 27): 15.5 ± 2.4 -Disease duration (years) | P: n.s. -Disease duration (years) | Survivin low, erosive RA ( n = 61): 13.6 ± 1.2 -Disease duration (years) | P: 0.0002 -Disease duration (years) | Survivin low, non-erosive RA ( n = 42) †: 8.3 ± 1.4 -Age (years) | Survivin high, erosive RA ( n = 27): 58 ± 3 -Age (years) | P: n.s. -Age (years) | Survivin low, erosive RA ( n = 61): 60 ± 2 -Age (years) | P: 0.05 -Age (years) | Survivin low, non-erosive RA ( n = 42) †: 53 ± 3 -Rheumatoid factor-positive ( n ) | Survivin high, erosive RA ( n = 27): 25 -Rheumatoid factor-positive ( n ) | P: n.s. -Rheumatoid factor-positive ( n ) | Survivin low, erosive RA ( n = 61): 53 -Rheumatoid factor-positive ( n ) | P: <0.0001 -Rheumatoid factor-positive ( n ) | Survivin low, non-erosive RA ( n = 42) †: 10 -C-reactive protein (mg/l) | Survivin high, erosive RA ( n = 27): 45 ± 9 -C-reactive protein (mg/l) | P: 0.035 -C-reactive protein (mg/l) | Survivin low, erosive RA ( n = 61): 29 ± 5 -C-reactive protein (mg/l) | P: n.s. -C-reactive protein (mg/l) | Survivin low, non-erosive RA ( n = 42) †: 39 ± 7 -White blood cell count (× 10 9 /ml) -Blood | Survivin high, erosive RA ( n = 27): 8.7 ± 0.6 -Blood | P: 0.038 -Blood | Survivin low, erosive RA ( n = 61): 7.2 ± 0.3 -Blood | P: n.s. -Blood | Survivin low, non-erosive RA ( n = 42) †: 7.1 ± 0.3 -Synovial fluid | Survivin high, erosive RA ( n = 27): 10.8 ± 1.9 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, erosive RA ( n = 61): 11.2 ± 2.9 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 13.1 ± 2.8 \ No newline at end of file +Survivin levels (pg/ml) > Blood | Survivin high, erosive RA ( n = 27): 1180 ± 309 +Survivin levels (pg/ml) > Blood | P: <0.0001 +Survivin levels (pg/ml) > Blood | Survivin low, erosive RA ( n = 61): 97 ± 9 +Survivin levels (pg/ml) > Blood | P: 0.013 +Survivin levels (pg/ml) > Blood | Survivin low, non-erosive RA ( n = 42) †: 127 ± 5 +Survivin levels (pg/ml) > Synovial fluid | Survivin high, erosive RA ( n = 27): 1039 ± 523 +Survivin levels (pg/ml) > Synovial fluid | P: 0.016 +Survivin levels (pg/ml) > Synovial fluid | Survivin low, erosive RA ( n = 61): 132 ± 4 +Survivin levels (pg/ml) > Synovial fluid | P: n.s. +Survivin levels (pg/ml) > Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 124 ± 2 +Survivin levels (pg/ml) > Disease duration (years) | Survivin high, erosive RA ( n = 27): 15.5 ± 2.4 +Survivin levels (pg/ml) > Disease duration (years) | P: n.s. +Survivin levels (pg/ml) > Disease duration (years) | Survivin low, erosive RA ( n = 61): 13.6 ± 1.2 +Survivin levels (pg/ml) > Disease duration (years) | P: 0.0002 +Survivin levels (pg/ml) > Disease duration (years) | Survivin low, non-erosive RA ( n = 42) †: 8.3 ± 1.4 +Survivin levels (pg/ml) > Age (years) | Survivin high, erosive RA ( n = 27): 58 ± 3 +Survivin levels (pg/ml) > Age (years) | P: n.s. +Survivin levels (pg/ml) > Age (years) | Survivin low, erosive RA ( n = 61): 60 ± 2 +Survivin levels (pg/ml) > Age (years) | P: 0.05 +Survivin levels (pg/ml) > Age (years) | Survivin low, non-erosive RA ( n = 42) †: 53 ± 3 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin high, erosive RA ( n = 27): 25 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | P: n.s. +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin low, erosive RA ( n = 61): 53 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | P: <0.0001 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin low, non-erosive RA ( n = 42) †: 10 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin high, erosive RA ( n = 27): 45 ± 9 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | P: 0.035 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin low, erosive RA ( n = 61): 29 ± 5 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | P: n.s. +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin low, non-erosive RA ( n = 42) †: 39 ± 7 +White blood cell count (× 10 9 /ml) > Blood | Survivin high, erosive RA ( n = 27): 8.7 ± 0.6 +White blood cell count (× 10 9 /ml) > Blood | P: 0.038 +White blood cell count (× 10 9 /ml) > Blood | Survivin low, erosive RA ( n = 61): 7.2 ± 0.3 +White blood cell count (× 10 9 /ml) > Blood | P: n.s. +White blood cell count (× 10 9 /ml) > Blood | Survivin low, non-erosive RA ( n = 42) †: 7.1 ± 0.3 +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin high, erosive RA ( n = 27): 10.8 ± 1.9 +White blood cell count (× 10 9 /ml) > Synovial fluid | P: n.s. +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin low, erosive RA ( n = 61): 11.2 ± 2.9 +White blood cell count (× 10 9 /ml) > Synovial fluid | P: n.s. +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 13.1 ± 2.8 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt index ca094f3..b3130fa 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt @@ -2,35 +2,31 @@ Age [mean (S.D.)] | Group I > Controls (n = 10): 40.5 (9.6) Age [mean (S.D.)] | Group II > Renal Dysfunction (n = 13): 46.5 (15.0) Age [mean (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 45.1 (11.1) Age [mean (S.D.)] | P-value: NS -Race [number (%)] -Caucasian | Group I > Controls (n = 10): 5 (50) -Caucasian | Group II > Renal Dysfunction (n = 13): 1 (8) -Caucasian | Group III > Diabetes and Renal Dysfunction (n = 7): 0 -Black | Group I > Controls (n = 10): 3 (30) -Black | Group II > Renal Dysfunction (n = 13): 12 (92) -Black | Group III > Diabetes and Renal Dysfunction (n = 7): 6 (86) -Black | P-value: 0.02 § -Other | Group I > Controls (n = 10): 2 (20) -Other | Group II > Renal Dysfunction (n = 13): 0 -Other | Group III > Diabetes and Renal Dysfunction (n = 7): 1 (14) -Sex [number (%)] -Male | Group I > Controls (n = 10): 5 (50) -Male | Group II > Renal Dysfunction (n = 13): 7 (54) -Male | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) -Male | P-value: NS -Female | Group I > Controls (n = 10): 5 (50) -Female | Group II > Renal Dysfunction (n = 13): 6 (46) -Female | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) -Weight -[mean kg (S.D.)] | Group I > Controls (n = 10): 75.0 (13.4) -[mean kg (S.D.)] | Group II > Renal Dysfunction (n = 13): 83.9 (23.1) -[mean kg (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 86.0 (25.0) -[mean kg (S.D.)] | P-value: NS -CAD [number (%)] -Yes | Group I > Controls (n = 10): 1 (10) -Yes | Group II > Renal Dysfunction (n = 13): 2 (15) -Yes | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) -Yes | P-value: NS -No | Group I > Controls (n = 10): 9 (90) -No | Group II > Renal Dysfunction (n = 13): 11 (85) -No | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) \ No newline at end of file +Race [number (%)] > Caucasian | Group I > Controls (n = 10): 5 (50) +Race [number (%)] > Caucasian | Group II > Renal Dysfunction (n = 13): 1 (8) +Race [number (%)] > Caucasian | Group III > Diabetes and Renal Dysfunction (n = 7): 0 +Race [number (%)] > Black | Group I > Controls (n = 10): 3 (30) +Race [number (%)] > Black | Group II > Renal Dysfunction (n = 13): 12 (92) +Race [number (%)] > Black | Group III > Diabetes and Renal Dysfunction (n = 7): 6 (86) +Race [number (%)] > Black | P-value: 0.02 § +Race [number (%)] > Other | Group I > Controls (n = 10): 2 (20) +Race [number (%)] > Other | Group II > Renal Dysfunction (n = 13): 0 +Race [number (%)] > Other | Group III > Diabetes and Renal Dysfunction (n = 7): 1 (14) +Sex [number (%)] > Male | Group I > Controls (n = 10): 5 (50) +Sex [number (%)] > Male | Group II > Renal Dysfunction (n = 13): 7 (54) +Sex [number (%)] > Male | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) +Sex [number (%)] > Male | P-value: NS +Sex [number (%)] > Female | Group I > Controls (n = 10): 5 (50) +Sex [number (%)] > Female | Group II > Renal Dysfunction (n = 13): 6 (46) +Sex [number (%)] > Female | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) +Weight > [mean kg (S.D.)] | Group I > Controls (n = 10): 75.0 (13.4) +Weight > [mean kg (S.D.)] | Group II > Renal Dysfunction (n = 13): 83.9 (23.1) +Weight > [mean kg (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 86.0 (25.0) +Weight > [mean kg (S.D.)] | P-value: NS +CAD [number (%)] > Yes | Group I > Controls (n = 10): 1 (10) +CAD [number (%)] > Yes | Group II > Renal Dysfunction (n = 13): 2 (15) +CAD [number (%)] > Yes | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) +CAD [number (%)] > Yes | P-value: NS +CAD [number (%)] > No | Group I > Controls (n = 10): 9 (90) +CAD [number (%)] > No | Group II > Renal Dysfunction (n = 13): 11 (85) +CAD [number (%)] > No | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt index 3c87195..e977ca4 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt @@ -1,4 +1,3 @@ -1998 Municipality of Bologna | resident population > N.: 2398 Municipality of Bologna | living abroad > %: 0.71 Municipality of Bologna | no fixed abode > %: 0.12 @@ -13,7 +12,6 @@ Emilia Romagna | refusals objectors > %: 0.29 Emilia Romagna | immigrated > %: 0.22 Emilia Romagna | delays > %: 0.51 Emilia Romagna | other* > %: 0.22 -1999 Municipality of Bologna | resident population > N.: 2560 Municipality of Bologna | living abroad > %: 1.09 Municipality of Bologna | no fixed abode > %: 0.43 @@ -28,7 +26,6 @@ Emilia Romagna | refusals objectors > %: 0.35 Emilia Romagna | immigrated > %: 0.22 Emilia Romagna | delays > %: 0.37 Emilia Romagna | other* > %: 0.11 -2000 Municipality of Bologna | resident population > N.: 2429 Municipality of Bologna | living abroad > %: 0,00 Municipality of Bologna | no fixed abode > %: 0.08 @@ -43,7 +40,6 @@ Emilia Romagna | refusals objectors > %: 0.20 Emilia Romagna | immigrated > %: 0.40 Emilia Romagna | delays > %: 0.50 Emilia Romagna | other* > %: 0.2 -2001 Municipality of Bologna | resident population > N.: 2619 Municipality of Bologna | living abroad > %: 0.04 Municipality of Bologna | no fixed abode > %: 0.19 @@ -58,7 +54,6 @@ Emilia Romagna | refusals objectors > %: 0.60 Emilia Romagna | immigrated > %: 0.26 Emilia Romagna | delays > %: 0.58 Emilia Romagna | other* > %: 0.25 -2002 Municipality of Bologna | resident population > N.: 2706 Municipality of Bologna | living abroad > %: 0.00 Municipality of Bologna | no fixed abode > %: 0.04 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt index 9544c37..94cd002 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt @@ -1,51 +1,48 @@ -Cigarettes/day -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.46 -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.02 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.24 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.44 -Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.027 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: 0.35 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.095 -Eosinophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.19 -Eosinophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS -Eosinophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.39 -Eosinophils sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.057 -Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > rho: -0.11 -Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > p-value: NS -Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > rho: -0.44 -Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > p-value: 0.029 -CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: 0.69 -CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.002 -CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.46 -CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: 0.029 -EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: -0.79 -EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.001 -EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.02 -EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: NS -Pack-years smoking -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.48 -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.043 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.21 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS -FEV 1 post BD, %pred . -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.31 -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: 0.15 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.41 -Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.046 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: -0.22 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > rho: -0.54 -IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > p-value: 0.007 -IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > rho: 0.15 -IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > p-value: NS -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.33 -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: NS -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.18 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS -AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.53 -AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.02 -AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.09 -AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS \ No newline at end of file +Cigarettes/day > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.46 +Cigarettes/day > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.02 +Cigarettes/day > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.24 +Cigarettes/day > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +Cigarettes/day > Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.44 +Cigarettes/day > Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.027 +Cigarettes/day > Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: 0.35 +Cigarettes/day > Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.095 +Cigarettes/day > Eosinophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.19 +Cigarettes/day > Eosinophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS +Cigarettes/day > Eosinophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.39 +Cigarettes/day > Eosinophils sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.057 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > rho: -0.11 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > p-value: NS +Cigarettes/day > Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > rho: -0.44 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > p-value: 0.029 +Cigarettes/day > CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: 0.69 +Cigarettes/day > CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.002 +Cigarettes/day > CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.46 +Cigarettes/day > CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: 0.029 +Cigarettes/day > EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: -0.79 +Cigarettes/day > EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.001 +Cigarettes/day > EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.02 +Cigarettes/day > EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: NS +Pack-years smoking > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.48 +Pack-years smoking > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.043 +Pack-years smoking > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.21 +Pack-years smoking > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.31 +FEV 1 post BD, %pred . > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS +FEV 1 post BD, %pred . > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: 0.15 +FEV 1 post BD, %pred . > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.41 +FEV 1 post BD, %pred . > Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.046 +FEV 1 post BD, %pred . > Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: -0.22 +FEV 1 post BD, %pred . > Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > rho: -0.54 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > p-value: 0.007 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > rho: 0.15 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.33 +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: NS +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.18 +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.53 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.02 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.09 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt index 65aa681..15bb6b3 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt @@ -1,23 +1,18 @@ -Primary prevention (7683 with no prior CVD) -Total CVD events† | Allocated treatment > Fenofibrate: 298 -Total CVD events† | Allocated treatment > Placebo: 385 -Total CVD events† | Power to detect effect at 2 P < 0.05*: 93% -Secondary prevention (2112 with prior CVD) -Total CVD events | Allocated treatment > Fenofibrate: 229 -Total CVD events | Allocated treatment > Placebo: 288 -Total CVD events | Power to detect effect at 2 P < 0.05*: 83% -Men (6139) -Total CVD events | Allocated treatment > Fenofibrate: 392 -Total CVD events | Allocated treatment > Placebo: 503 -Total CVD events | Power to detect effect at 2 P < 0.05*: 98% -Women (3656) -Total CVD events | Allocated treatment > Fenofibrate: 133 -Total CVD events | Allocated treatment > Placebo: 171 -Total CVD events | Power to detect effect at 2 P < 0.05*: 60% -All patients (9795) -Total CVD events | Allocated treatment > Fenofibrate: 525 -Total CVD events | Allocated treatment > Placebo: 675 -Total CVD events | Power to detect effect at 2 P < 0.05*: 99% -Total CHD events | Allocated treatment > Fenofibrate: 219 -Total CHD events | Allocated treatment > Placebo: 281 -Total CHD events | Power to detect effect at 2 P < 0.05*: 80% \ No newline at end of file +Primary prevention (7683 with no prior CVD) > Total CVD events† | Allocated treatment > Fenofibrate: 298 +Primary prevention (7683 with no prior CVD) > Total CVD events† | Allocated treatment > Placebo: 385 +Primary prevention (7683 with no prior CVD) > Total CVD events† | Power to detect effect at 2 P < 0.05*: 93% +Secondary prevention (2112 with prior CVD) > Total CVD events | Allocated treatment > Fenofibrate: 229 +Secondary prevention (2112 with prior CVD) > Total CVD events | Allocated treatment > Placebo: 288 +Secondary prevention (2112 with prior CVD) > Total CVD events | Power to detect effect at 2 P < 0.05*: 83% +Men (6139) > Total CVD events | Allocated treatment > Fenofibrate: 392 +Men (6139) > Total CVD events | Allocated treatment > Placebo: 503 +Men (6139) > Total CVD events | Power to detect effect at 2 P < 0.05*: 98% +Women (3656) > Total CVD events | Allocated treatment > Fenofibrate: 133 +Women (3656) > Total CVD events | Allocated treatment > Placebo: 171 +Women (3656) > Total CVD events | Power to detect effect at 2 P < 0.05*: 60% +All patients (9795) > Total CVD events | Allocated treatment > Fenofibrate: 525 +All patients (9795) > Total CVD events | Allocated treatment > Placebo: 675 +All patients (9795) > Total CVD events | Power to detect effect at 2 P < 0.05*: 99% +All patients (9795) > Total CHD events | Allocated treatment > Fenofibrate: 219 +All patients (9795) > Total CHD events | Allocated treatment > Placebo: 281 +All patients (9795) > Total CHD events | Power to detect effect at 2 P < 0.05*: 80% \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt index b885f76..5c3bc6a 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt @@ -7,28 +7,27 @@ Wheezing | P value for comparison of proportions: 0.43 Chest retractions | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) Chest retractions | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 25.8 (8/31) Chest retractions | P value for comparison of proportions: 0.33 -Feeding pattern: -Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) -Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 54.8 (17/31) -Normal feeding | P value for comparison of proportions: 0.80 -Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) -Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 41.9 (13/31) -Less than normal | P value for comparison of proportions: 0.61 -Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) -Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) -Unable to feed | P value for comparison of proportions: 1.00 -Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 20 (6/30) -Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 35.5 (11/31) -Vomiting | P value for comparison of proportions: 0.25 -Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) -Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 0 (0/31) -Tremors | P value for comparison of proportions: N/A -Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) -Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 6.5 (2/31) -Pallor | P value for comparison of proportions: 0 -Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 23.3 (7/30) -Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 19.4 (6/31) -Has had a visit to a physician | P value for comparison of proportions: 0.42 -Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 3.3 (1/30) -Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) -Has visited an emergency department or been hospitalized | P value for comparison of proportions: 1.00 \ No newline at end of file +Feeding pattern: > Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) +Feeding pattern: > Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 54.8 (17/31) +Feeding pattern: > Normal feeding | P value for comparison of proportions: 0.80 +Feeding pattern: > Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) +Feeding pattern: > Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 41.9 (13/31) +Feeding pattern: > Less than normal | P value for comparison of proportions: 0.61 +Feeding pattern: > Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) +Feeding pattern: > Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) +Feeding pattern: > Unable to feed | P value for comparison of proportions: 1.00 +Feeding pattern: > Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 20 (6/30) +Feeding pattern: > Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 35.5 (11/31) +Feeding pattern: > Vomiting | P value for comparison of proportions: 0.25 +Feeding pattern: > Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) +Feeding pattern: > Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 0 (0/31) +Feeding pattern: > Tremors | P value for comparison of proportions: N/A +Feeding pattern: > Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) +Feeding pattern: > Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 6.5 (2/31) +Feeding pattern: > Pallor | P value for comparison of proportions: 0 +Feeding pattern: > Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 23.3 (7/30) +Feeding pattern: > Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 19.4 (6/31) +Feeding pattern: > Has had a visit to a physician | P value for comparison of proportions: 0.42 +Feeding pattern: > Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 3.3 (1/30) +Feeding pattern: > Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) +Feeding pattern: > Has visited an emergency department or been hospitalized | P value for comparison of proportions: 1.00 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt index 608389e..fa00331 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt @@ -35,20 +35,19 @@ Coffee drinking | Formulation A: 7 (41.2%) Coffee drinking | Formulation B: 7 (41.2%) Coffee drinking | Total: 14 (41.2%) Coffee drinking | p: 1.00 Δ -Causes of renal failure -Diabetes Mellitus | Formulation A: 7 (46.7%) -Diabetes Mellitus | Formulation B: 6 (40.0%) -Diabetes Mellitus | Total: 13 (43.3%) -Diabetes Mellitus | p: 0.71 Δ -Hypertension | Formulation A: 5 (33.3%) -Hypertension | Formulation B: 4 (26.7%) -Hypertension | Total: 9 (30.0%) -Hypertension | p: 1.00 ! -Other glomerulopathies | Formulation A: 1 (6.7%) -Other glomerulopathies | Formulation B: 1 (6.7%) -Other glomerulopathies | Total: 2 (6.7%) -Other glomerulopathies | p: 1.00 ! -Cystic disease | Formulation A: 1 (6.7%) -Cystic disease | Formulation B: 3 (20.0%) -Cystic disease | Total: 4 (5.6%) -Cystic disease | p: 0.60 ! \ No newline at end of file +Causes of renal failure > Diabetes Mellitus | Formulation A: 7 (46.7%) +Causes of renal failure > Diabetes Mellitus | Formulation B: 6 (40.0%) +Causes of renal failure > Diabetes Mellitus | Total: 13 (43.3%) +Causes of renal failure > Diabetes Mellitus | p: 0.71 Δ +Causes of renal failure > Hypertension | Formulation A: 5 (33.3%) +Causes of renal failure > Hypertension | Formulation B: 4 (26.7%) +Causes of renal failure > Hypertension | Total: 9 (30.0%) +Causes of renal failure > Hypertension | p: 1.00 ! +Causes of renal failure > Other glomerulopathies | Formulation A: 1 (6.7%) +Causes of renal failure > Other glomerulopathies | Formulation B: 1 (6.7%) +Causes of renal failure > Other glomerulopathies | Total: 2 (6.7%) +Causes of renal failure > Other glomerulopathies | p: 1.00 ! +Causes of renal failure > Cystic disease | Formulation A: 1 (6.7%) +Causes of renal failure > Cystic disease | Formulation B: 3 (20.0%) +Causes of renal failure > Cystic disease | Total: 4 (5.6%) +Causes of renal failure > Cystic disease | p: 0.60 ! \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt index 8ef65a1..131ced2 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt @@ -1,54 +1,48 @@ -Lactate (mg/dl) -Lornoxicam | Baseline: 25.2 ± 4.1 -Lornoxicam | Hours after the start of infusion > 24: 25.0 ± 3.9 -Lornoxicam | Hours after the start of infusion > 48: 25.9 ± 5.2 -Lornoxicam | Hours after the start of infusion > 72: 26.2 ± 3.7 -Placebo | Baseline: 26.3 ± 3.8 -Placebo | Hours after the start of infusion > 24: 26.7 ± 2.9 -Placebo | Hours after the start of infusion > 48: 27.0 ± 3.1 -Placebo | Hours after the start of infusion > 72: 26.9 ± 4.8 -Platelets (×10 9 /l) -Lornoxicam | Baseline: 192.9 ± 16.5 -Lornoxicam | Hours after the start of infusion > 24: 193.5 ± 15.0 -Lornoxicam | Hours after the start of infusion > 48: 178.1 ± 15.4 -Lornoxicam | Hours after the start of infusion > 72: 182.9 ± 15.6 -Placebo | Baseline: 188.5 ± 14.4 -Placebo | Hours after the start of infusion > 24: 190.8 ± 15.1 -Placebo | Hours after the start of infusion > 48: 188.7 ± 13.3 -Placebo | Hours after the start of infusion > 72: 190.5 ± 16.7 -Leucocytes (×10 9 /l) -Lornoxicam | Baseline: 14 ± 8.3 -Lornoxicam | Hours after the start of infusion > 24: 15.8 ± 8.3 -Lornoxicam | Hours after the start of infusion > 48: 16.0 ± 7.8 -Lornoxicam | Hours after the start of infusion > 72: 15.9 ± 6.2 -Placebo | Baseline: 13.5 ± 6.6 -Placebo | Hours after the start of infusion > 24: 14.7 ± 4.7 -Placebo | Hours after the start of infusion > 48: 15.7 ± 6.7 -Placebo | Hours after the start of infusion > 72: 14.8 ± 7.4 -Bilirubin (mg/dl) -Lornoxicam | Baseline: 0.89 ± 0.38 -Lornoxicam | Hours after the start of infusion > 24: 0.90 ± 0.45 -Lornoxicam | Hours after the start of infusion > 48: 0.93 ± 0.33 -Lornoxicam | Hours after the start of infusion > 72: 0.90 ± 0.34 -Placebo | Baseline: 0.90 ± 0.62 -Placebo | Hours after the start of infusion > 24: 0.91 ± 0.38 -Placebo | Hours after the start of infusion > 48: 0.92 ± 0.28 -Placebo | Hours after the start of infusion > 72: 0.91 ± 0.36 -Alanine aminotransferase (IU/l) -Lornoxicam | Baseline: 35.4 ± 5.5 -Lornoxicam | Hours after the start of infusion > 24: 36.0 ± 10.8 -Lornoxicam | Hours after the start of infusion > 48: 35.1 ± 8.6 -Lornoxicam | Hours after the start of infusion > 72: 36.7 ± 8.4 -Placebo | Baseline: 35.4 ± 7.4 -Placebo | Hours after the start of infusion > 24: 35.5 ± 5.2 -Placebo | Hours after the start of infusion > 48: 36.2 ± 6.0 -Placebo | Hours after the start of infusion > 72: 37.4 ± 4.9 -Creatinine (mg/dl) -Lornoxicam | Baseline: 1.13 ± 0.96 -Lornoxicam | Hours after the start of infusion > 24: 1.15 ± 0.85 -Lornoxicam | Hours after the start of infusion > 48: 1.2 ± 0.3 -Lornoxicam | Hours after the start of infusion > 72: 1.28 ± 0.8 -Placebo | Baseline: 1.01 ± 0.91 -Placebo | Hours after the start of infusion > 24: 1.1 ± 0.65 -Placebo | Hours after the start of infusion > 48: 1.08 ± 0.7 -Placebo | Hours after the start of infusion > 72: 1.1 ± 0.8 \ No newline at end of file +Lactate (mg/dl) > Lornoxicam | Baseline: 25.2 ± 4.1 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 25.0 ± 3.9 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 25.9 ± 5.2 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 26.2 ± 3.7 +Lactate (mg/dl) > Placebo | Baseline: 26.3 ± 3.8 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 24: 26.7 ± 2.9 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 48: 27.0 ± 3.1 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 72: 26.9 ± 4.8 +Platelets (×10 9 /l) > Lornoxicam | Baseline: 192.9 ± 16.5 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 24: 193.5 ± 15.0 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 48: 178.1 ± 15.4 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 72: 182.9 ± 15.6 +Platelets (×10 9 /l) > Placebo | Baseline: 188.5 ± 14.4 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 24: 190.8 ± 15.1 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 48: 188.7 ± 13.3 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 72: 190.5 ± 16.7 +Leucocytes (×10 9 /l) > Lornoxicam | Baseline: 14 ± 8.3 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 24: 15.8 ± 8.3 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 48: 16.0 ± 7.8 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 72: 15.9 ± 6.2 +Leucocytes (×10 9 /l) > Placebo | Baseline: 13.5 ± 6.6 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 24: 14.7 ± 4.7 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 48: 15.7 ± 6.7 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 72: 14.8 ± 7.4 +Bilirubin (mg/dl) > Lornoxicam | Baseline: 0.89 ± 0.38 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 0.90 ± 0.45 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 0.93 ± 0.33 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 0.90 ± 0.34 +Bilirubin (mg/dl) > Placebo | Baseline: 0.90 ± 0.62 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 24: 0.91 ± 0.38 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 48: 0.92 ± 0.28 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 72: 0.91 ± 0.36 +Alanine aminotransferase (IU/l) > Lornoxicam | Baseline: 35.4 ± 5.5 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 24: 36.0 ± 10.8 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 48: 35.1 ± 8.6 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 72: 36.7 ± 8.4 +Alanine aminotransferase (IU/l) > Placebo | Baseline: 35.4 ± 7.4 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 24: 35.5 ± 5.2 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 48: 36.2 ± 6.0 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 72: 37.4 ± 4.9 +Creatinine (mg/dl) > Lornoxicam | Baseline: 1.13 ± 0.96 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 1.15 ± 0.85 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 1.2 ± 0.3 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 1.28 ± 0.8 +Creatinine (mg/dl) > Placebo | Baseline: 1.01 ± 0.91 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 24: 1.1 ± 0.65 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 48: 1.08 ± 0.7 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 72: 1.1 ± 0.8 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt index 5eb06cb..e6f7dac 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt @@ -1,131 +1,128 @@ -DD -α 1 = 0.005 | Radial Score Test: 0.02 -α 1 = 0.005 | DIR Score Test: 0.02 -α 1 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.005 | Tango's Test ( τ = 5): 0.02 -α 1 = 0.005 | LRS DIR Test: 0.02 -α 1 = 0.005 | LRS DD Test: 0.02 -α 1 = 0.005 | Stone's Test: 0.02 -α 1 = 0.05 | Radial Score Test: 0.02 -α 1 = 0.05 | DIR Score Test: 0.02 -α 1 = 0.05 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.05 | Tango's Test ( τ = 5): 0.03 -α 1 = 0.05 | LRS DIR Test: 0.02 -α 1 = 0.05 | LRS DD Test: 0.03 -α 1 = 0.05 | Stone's Test: 0.02 -α 1 = 0.1 | Radial Score Test: 0.02 -α 1 = 0.1 | DIR Score Test: 0.02 -α 1 = 0.1 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.1 | Tango's Test ( τ = 5): 0.03 -α 1 = 0.1 | LRS DIR Test: 0.02 -α 1 = 0.1 | LRS DD Test: 0.03 -α 1 = 0.1 | Stone's Test: 0.03 -α 1 = 1 | Radial Score Test: 0.05 -α 1 = 1 | DIR Score Test: 0.02 -α 1 = 1 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 1 | Cuzick and Edwards' Test ( k = 7): 0.03 -α 1 = 1 | Tango's Test ( τ = 5): 0.04 -α 1 = 1 | LRS DIR Test: 0.02 -α 1 = 1 | LRS DD Test: 0.04 -α 1 = 1 | Stone's Test: 0.05 -α 1 = 2 | Radial Score Test: 0.03 -α 1 = 2 | DIR Score Test: 0.02 -α 1 = 2 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 2 | Cuzick and Edwards' Test ( k = 7): 0.04 -α 1 = 2 | Tango's Test ( τ = 5): 0.02 -α 1 = 2 | LRS DIR Test: 0.03 -α 1 = 2 | LRS DD Test: 0.01 -α 1 = 2 | Stone's Test: 0.03 -α 1 = 10 | Radial Score Test: 0.04 -α 1 = 10 | DIR Score Test: 0.02 -α 1 = 10 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 10 | Cuzick and Edwards' Test ( k = 7): 0.05 -α 1 = 10 | Tango's Test ( τ = 5): 0.03 -α 1 = 10 | LRS DIR Test: 0.02 -α 1 = 10 | LRS DD Test: 0.03 -α 1 = 10 | Stone's Test: 0.03 -DIR -α 3 and α 4 = 0.005 | Radial Score Test: 0.03 -α 3 and α 4 = 0.005 | DIR Score Test: 0.04 -α 3 and α 4 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 -α 3 and α 4 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 3 and α 4 = 0.005 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 0.005 | LRS DIR Test: 0.04 -α 3 and α 4 = 0.005 | LRS DD Test: 0.03 -α 3 and α 4 = 0.005 | Stone's Test: 0.02 -α 3 and α 4 = 0.1 | Radial Score Test: 0.03 -α 3 and α 4 = 0.1 | DIR Score Test: 0.04 -α 3 and α 4 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 -α 3 and α 4 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 3 and α 4 = 0.1 | Tango's Test ( τ = 5): 0.02 -α 3 and α 4 = 0.1 | LRS DIR Test: 0.05 -α 3 and α 4 = 0.1 | LRS DD Test: 0.02 -α 3 and α 4 = 0.1 | Stone's Test: 0.02 -α 3 and α 4 = 0.2 | Radial Score Test: 0.03 -α 3 and α 4 = 0.2 | DIR Score Test: 0.03 -α 3 and α 4 = 0.2 | Besag and Newell's Test ( k = 7): 0.01 -α 3 and α 4 = 0.2 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 3 and α 4 = 0.2 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 0.2 | LRS DIR Test: 0.01 -α 3 and α 4 = 0.2 | LRS DD Test: 0.03 -α 3 and α 4 = 0.2 | Stone's Test: 0.02 -α 3 and α 4 = 0.5 | Radial Score Test: 0.03 -α 3 and α 4 = 0.5 | DIR Score Test: 0.00 -α 3 and α 4 = 0.5 | Besag and Newell's Test ( k = 7): 0.02 -α 3 and α 4 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 3 and α 4 = 0.5 | Tango's Test ( τ = 5): 0.02 -α 3 and α 4 = 0.5 | LRS DIR Test: 0.00 -α 3 and α 4 = 0.5 | LRS DD Test: 0.02 -α 3 and α 4 = 0.5 | Stone's Test: 0.02 -α 3 and α 4 = 1 | Radial Score Test: 0.03 -α 3 and α 4 = 1 | DIR Score Test: 0.00 -α 3 and α 4 = 1 | Besag and Newell's Test ( k = 7): 0.03 -α 3 and α 4 = 1 | Cuzick and Edwards' Test ( k = 7): 0.00 -α 3 and α 4 = 1 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 1 | LRS DIR Test: 0.00 -α 3 and α 4 = 1 | LRS DD Test: 0.03 -α 3 and α 4 = 1 | Stone's Test: 0.02 -α 3 and α 4 = 2 | Radial Score Test: 0.03 -α 3 and α 4 = 2 | DIR Score Test: 0.00 -α 3 and α 4 = 2 | Besag and Newell's Test ( k = 7): 0.04 -α 3 and α 4 = 2 | Cuzick and Edwards' Test ( k = 7): 0.00 -α 3 and α 4 = 2 | Tango's Test ( τ = 5): 0.04 -α 3 and α 4 = 2 | LRS DIR Test: 0.00 -α 3 and α 4 = 2 | LRS DD Test: 0.04 -α 3 and α 4 = 2 | Stone's Test: 0.03 -PKDD α 1 = 0.005 -α 2 = 0.05 | Radial Score Test: 0.03 -α 2 = 0.05 | DIR Score Test: 0.02 -α 2 = 0.05 | Besag and Newell's Test ( k = 7): 0.02 -α 2 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 2 = 0.05 | Tango's Test ( τ = 5): 0.01 -α 2 = 0.05 | LRS DIR Test: 0.02 -α 2 = 0.05 | LRS DD Test: 0.02 -α 2 = 0.05 | Stone's Test: 0.01 -α 2 = 0.1 | Radial Score Test: 0.04 -α 2 = 0.1 | DIR Score Test: 0.02 -α 2 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 -α 2 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 0.1 | Tango's Test ( τ = 5): 0.01 -α 2 = 0.1 | LRS DIR Test: 0.02 -α 2 = 0.1 | LRS DD Test: 0.01 -α 2 = 0.1 | Stone's Test: 0.00 -α 2 = 0.5 | Radial Score Test: 0.03 -α 2 = 0.5 | DIR Score Test: 0.02 -α 2 = 0.5 | Besag and Newell's Test ( k = 7): 0.04 -α 2 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 0.5 | Tango's Test ( τ = 5): 0.00 -α 2 = 0.5 | LRS DIR Test: 0.02 -α 2 = 0.5 | LRS DD Test: 0.00 -α 2 = 0.5 | Stone's Test: 0.00 -α 2 = 1 | Radial Score Test: 0.01 -α 2 = 1 | DIR Score Test: 0.02 -α 2 = 1 | Besag and Newell's Test ( k = 7): 0.04 -α 2 = 1 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 1 | Tango's Test ( τ = 5): 0.00 -α 2 = 1 | LRS DIR Test: 0.02 -α 2 = 1 | LRS DD Test: 0.00 -α 2 = 1 | Stone's Test: 0.00 \ No newline at end of file +DD > α 1 = 0.005 | Radial Score Test: 0.02 +DD > α 1 = 0.005 | DIR Score Test: 0.02 +DD > α 1 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.005 | Tango's Test ( τ = 5): 0.02 +DD > α 1 = 0.005 | LRS DIR Test: 0.02 +DD > α 1 = 0.005 | LRS DD Test: 0.02 +DD > α 1 = 0.005 | Stone's Test: 0.02 +DD > α 1 = 0.05 | Radial Score Test: 0.02 +DD > α 1 = 0.05 | DIR Score Test: 0.02 +DD > α 1 = 0.05 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.05 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 0.05 | LRS DIR Test: 0.02 +DD > α 1 = 0.05 | LRS DD Test: 0.03 +DD > α 1 = 0.05 | Stone's Test: 0.02 +DD > α 1 = 0.1 | Radial Score Test: 0.02 +DD > α 1 = 0.1 | DIR Score Test: 0.02 +DD > α 1 = 0.1 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.1 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 0.1 | LRS DIR Test: 0.02 +DD > α 1 = 0.1 | LRS DD Test: 0.03 +DD > α 1 = 0.1 | Stone's Test: 0.03 +DD > α 1 = 1 | Radial Score Test: 0.05 +DD > α 1 = 1 | DIR Score Test: 0.02 +DD > α 1 = 1 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 1 | Cuzick and Edwards' Test ( k = 7): 0.03 +DD > α 1 = 1 | Tango's Test ( τ = 5): 0.04 +DD > α 1 = 1 | LRS DIR Test: 0.02 +DD > α 1 = 1 | LRS DD Test: 0.04 +DD > α 1 = 1 | Stone's Test: 0.05 +DD > α 1 = 2 | Radial Score Test: 0.03 +DD > α 1 = 2 | DIR Score Test: 0.02 +DD > α 1 = 2 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 2 | Cuzick and Edwards' Test ( k = 7): 0.04 +DD > α 1 = 2 | Tango's Test ( τ = 5): 0.02 +DD > α 1 = 2 | LRS DIR Test: 0.03 +DD > α 1 = 2 | LRS DD Test: 0.01 +DD > α 1 = 2 | Stone's Test: 0.03 +DD > α 1 = 10 | Radial Score Test: 0.04 +DD > α 1 = 10 | DIR Score Test: 0.02 +DD > α 1 = 10 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 10 | Cuzick and Edwards' Test ( k = 7): 0.05 +DD > α 1 = 10 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 10 | LRS DIR Test: 0.02 +DD > α 1 = 10 | LRS DD Test: 0.03 +DD > α 1 = 10 | Stone's Test: 0.03 +DIR > α 3 and α 4 = 0.005 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.005 | DIR Score Test: 0.04 +DIR > α 3 and α 4 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.005 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 0.005 | LRS DIR Test: 0.04 +DIR > α 3 and α 4 = 0.005 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 0.005 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.1 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.1 | DIR Score Test: 0.04 +DIR > α 3 and α 4 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.1 | Tango's Test ( τ = 5): 0.02 +DIR > α 3 and α 4 = 0.1 | LRS DIR Test: 0.05 +DIR > α 3 and α 4 = 0.1 | LRS DD Test: 0.02 +DIR > α 3 and α 4 = 0.1 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.2 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.2 | DIR Score Test: 0.03 +DIR > α 3 and α 4 = 0.2 | Besag and Newell's Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.2 | Cuzick and Edwards' Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.2 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 0.2 | LRS DIR Test: 0.01 +DIR > α 3 and α 4 = 0.2 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 0.2 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.5 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.5 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 0.5 | Besag and Newell's Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.5 | Tango's Test ( τ = 5): 0.02 +DIR > α 3 and α 4 = 0.5 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 0.5 | LRS DD Test: 0.02 +DIR > α 3 and α 4 = 0.5 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 1 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 1 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 1 | Besag and Newell's Test ( k = 7): 0.03 +DIR > α 3 and α 4 = 1 | Cuzick and Edwards' Test ( k = 7): 0.00 +DIR > α 3 and α 4 = 1 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 1 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 1 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 1 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 2 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 2 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 2 | Besag and Newell's Test ( k = 7): 0.04 +DIR > α 3 and α 4 = 2 | Cuzick and Edwards' Test ( k = 7): 0.00 +DIR > α 3 and α 4 = 2 | Tango's Test ( τ = 5): 0.04 +DIR > α 3 and α 4 = 2 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 2 | LRS DD Test: 0.04 +DIR > α 3 and α 4 = 2 | Stone's Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.05 | Radial Score Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.05 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Besag and Newell's Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Tango's Test ( τ = 5): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.05 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | LRS DD Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Stone's Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Radial Score Test: 0.04 +PKDD α 1 = 0.005 > α 2 = 0.1 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Tango's Test ( τ = 5): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | LRS DD Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Stone's Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | Radial Score Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.5 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.5 | Besag and Newell's Test ( k = 7): 0.04 +PKDD α 1 = 0.005 > α 2 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.5 | Tango's Test ( τ = 5): 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.5 | LRS DD Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | Stone's Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | Radial Score Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 1 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 1 | Besag and Newell's Test ( k = 7): 0.04 +PKDD α 1 = 0.005 > α 2 = 1 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 1 | Tango's Test ( τ = 5): 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 1 | LRS DD Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | Stone's Test: 0.00 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt index 1045e41..d9d5f56 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt @@ -1,49 +1,47 @@ -Variable 1 -Cathepsin K | Mean: 304.66 -Cathepsin K | Standard deviation: 677.607 -Variable 2 -Age (years) | Mean: 62.89 -Age (years) | Standard deviation: 11.1581 -Age (years) | n: 100 -Age (years) | Coeffficient: 0.0543 -Age (years) | Probability > | r |: 0.5915 -Rheumatoid factor (U/l) | Mean: 298.818 -Rheumatoid factor (U/l) | Standard deviation: 1136.49 -Rheumatoid factor (U/l) | n: 100 -Rheumatoid factor (U/l) | Coeffficient: 0.4761 -Rheumatoid factor (U/l) | Probability > | r |: < 0.0001 -Morning stiffness (min) | Mean: 32 -Morning stiffness (min) | Standard deviation: 38.7233 -Morning stiffness (min) | n: 100 -Morning stiffness (min) | Coeffficient: 0.1320 -Morning stiffness (min) | Probability > | r |: 0.1905 -Erythrocyte sedimentation rate (mm/hour) | Mean: 30.27 -Erythrocyte sedimentation rate (mm/hour) | Standard deviation: 20.8404 -Erythrocyte sedimentation rate (mm/hour) | n: 100 -Erythrocyte sedimentation rate (mm/hour) | Coeffficient: 0.2200 -Erythrocyte sedimentation rate (mm/hour) | Probability > | r |: 0.0279 -C-reactive protein (mg/l) | Mean: 24.96 -C-reactive protein (mg/l) | Standard deviation: 23.5032 -C-reactive protein (mg/l) | n: 100 -C-reactive protein (mg/l) | Coeffficient: 0.1121 -C-reactive protein (mg/l) | Probability > | r |: 0.2670 -Ritchie score | Mean: 11.31 -Ritchie score | Standard deviation: 10.3394 -Ritchie score | n: 100 -Ritchie score | Coeffficient: 0.1353 -Ritchie score | Probability > | r |: 0.1797 -Proximal interphalangeal score | Mean: 1.51 -Proximal interphalangeal score | Standard deviation: 2.69865 -Proximal interphalangeal score | n: 100 -Proximal interphalangeal score | Coeffficient: 0.2560 -Proximal interphalangeal score | Probability > | r |: 0.0101 -Disease activity score | Mean: 3.33283 -Disease activity score | Standard deviation: 1.43345 -Disease activity score | n: 100 -Disease activity score | Coeffficient: 0.2093 -Disease activity score | Probability > | r |: 0.0376 -Larsen score | Mean: 54.77 -Larsen score | Standard deviation: 49.3335 -Larsen score | n: 100 -Larsen score | Coeffficient: 0.2856 -Larsen score | Probability > | r |: 0.0040 \ No newline at end of file +Variable 1 > Cathepsin K | Mean: 304.66 +Variable 1 > Cathepsin K | Standard deviation: 677.607 +Variable 2 > Age (years) | Mean: 62.89 +Variable 2 > Age (years) | Standard deviation: 11.1581 +Variable 2 > Age (years) | n: 100 +Variable 2 > Age (years) | Coeffficient: 0.0543 +Variable 2 > Age (years) | Probability > | r |: 0.5915 +Variable 2 > Rheumatoid factor (U/l) | Mean: 298.818 +Variable 2 > Rheumatoid factor (U/l) | Standard deviation: 1136.49 +Variable 2 > Rheumatoid factor (U/l) | n: 100 +Variable 2 > Rheumatoid factor (U/l) | Coeffficient: 0.4761 +Variable 2 > Rheumatoid factor (U/l) | Probability > | r |: < 0.0001 +Variable 2 > Morning stiffness (min) | Mean: 32 +Variable 2 > Morning stiffness (min) | Standard deviation: 38.7233 +Variable 2 > Morning stiffness (min) | n: 100 +Variable 2 > Morning stiffness (min) | Coeffficient: 0.1320 +Variable 2 > Morning stiffness (min) | Probability > | r |: 0.1905 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Mean: 30.27 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Standard deviation: 20.8404 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | n: 100 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Coeffficient: 0.2200 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Probability > | r |: 0.0279 +Variable 2 > C-reactive protein (mg/l) | Mean: 24.96 +Variable 2 > C-reactive protein (mg/l) | Standard deviation: 23.5032 +Variable 2 > C-reactive protein (mg/l) | n: 100 +Variable 2 > C-reactive protein (mg/l) | Coeffficient: 0.1121 +Variable 2 > C-reactive protein (mg/l) | Probability > | r |: 0.2670 +Variable 2 > Ritchie score | Mean: 11.31 +Variable 2 > Ritchie score | Standard deviation: 10.3394 +Variable 2 > Ritchie score | n: 100 +Variable 2 > Ritchie score | Coeffficient: 0.1353 +Variable 2 > Ritchie score | Probability > | r |: 0.1797 +Variable 2 > Proximal interphalangeal score | Mean: 1.51 +Variable 2 > Proximal interphalangeal score | Standard deviation: 2.69865 +Variable 2 > Proximal interphalangeal score | n: 100 +Variable 2 > Proximal interphalangeal score | Coeffficient: 0.2560 +Variable 2 > Proximal interphalangeal score | Probability > | r |: 0.0101 +Variable 2 > Disease activity score | Mean: 3.33283 +Variable 2 > Disease activity score | Standard deviation: 1.43345 +Variable 2 > Disease activity score | n: 100 +Variable 2 > Disease activity score | Coeffficient: 0.2093 +Variable 2 > Disease activity score | Probability > | r |: 0.0376 +Variable 2 > Larsen score | Mean: 54.77 +Variable 2 > Larsen score | Standard deviation: 49.3335 +Variable 2 > Larsen score | n: 100 +Variable 2 > Larsen score | Coeffficient: 0.2856 +Variable 2 > Larsen score | Probability > | r |: 0.0040 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt index d827c07..7a6057f 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt @@ -2,17 +2,16 @@ Annual change in mL per pack-year to 1991: Coef Annual change in mL per pack-year to 1991: 95%CI Annual change in mL per pack-year to 1991: p value Annual change in mL per packs per day between 1991 and 2002: Coef -Quitters† -Men (n = 245) | Term: Linear -Men (n = 245) | Annual change in mL per pack-year to 1991: -0.1 -Men (n = 245) | Annual change in mL per pack-year to 1991: -0.4, 0.3 -Men (n = 245) | Annual change in mL per pack-year to 1991: 0.78 -Men (n = 245) | Annual change in mL per packs per day between 1991 and 2002: -14.3 -Women (n = 179) | Term: Linear -Women (n = 179) | Annual change in mL per pack-year to 1991: 1.5 -Women (n = 179) | Annual change in mL per pack-year to 1991: 0.3, 2.6 -Women (n = 179) | Annual change in mL per pack-year to 1991: 0.01 -Women (n = 179) | Annual change in mL per packs per day between 1991 and 2002: -6.4 +Quitters† > Men (n = 245) | Term: Linear +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: -0.1 +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: -0.4, 0.3 +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: 0.78 +Quitters† > Men (n = 245) | Annual change in mL per packs per day between 1991 and 2002: -14.3 +Quitters† > Women (n = 179) | Term: Linear +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 1.5 +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 0.3, 2.6 +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 0.01 +Quitters† > Women (n = 179) | Annual change in mL per packs per day between 1991 and 2002: -6.4 Term: Quadratic Annual change in mL per pack-year to 1991: -0.04 Annual change in mL per pack-year to 1991: -0.08,-0.01 @@ -23,17 +22,16 @@ Annual change in mL per pack-year to 1991: 0.0004 Annual change in mL per pack-year to 1991: 0.0001,0.0006 Annual change in mL per pack-year to 1991: 0.006 Annual change in mL per packs per day between 1991 and 2002: na -Persistent smokers† -Men (n = 595) | Term: Linear -Men (n = 595) | Annual change in mL per pack-year to 1991: -0.1 -Men (n = 595) | Annual change in mL per pack-year to 1991: -0.3, 0.12 -Men (n = 595) | Annual change in mL per pack-year to 1991: 0.41 -Men (n = 595) | Annual change in mL per packs per day between 1991 and 2002: -9.0 -Women (n = 556) | Term: Linear -Women (n = 556) | Annual change in mL per pack-year to 1991: 1.4 -Women (n = 556) | Annual change in mL per pack-year to 1991: 0.5, 2.3 -Women (n = 556) | Annual change in mL per pack-year to 1991: 0.001 -Women (n = 556) | Annual change in mL per packs per day between 1991 and 2002: -11.6 +Persistent smokers† > Men (n = 595) | Term: Linear +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: -0.1 +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: -0.3, 0.12 +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: 0.41 +Persistent smokers† > Men (n = 595) | Annual change in mL per packs per day between 1991 and 2002: -9.0 +Persistent smokers† > Women (n = 556) | Term: Linear +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 1.4 +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 0.5, 2.3 +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 0.001 +Persistent smokers† > Women (n = 556) | Annual change in mL per packs per day between 1991 and 2002: -11.6 Term: Quadratic Annual change in mL per pack-year to 1991: -0.06 Annual change in mL per pack-year to 1991: -0.08, -0.02 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt index 0c29c95..e57fefa 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt @@ -1,4 +1,3 @@ -2001 Municipality of Bologna | 12 months > DPT > %: 98.7 Municipality of Bologna | 12 months > Polio > %: 98.5 Municipality of Bologna | 12 months > Hepatitis B > %: 97.1 @@ -14,7 +13,6 @@ Emilia Romagna | 24 months > Hepatitis B > %: 98.0 Italy | 24 months > DPT > %: 96.1 Italy | 24 months > Polio > %: 96.0 Italy | 24 months > Hepatitis B > %: 94.7 -2002 Municipality of Bologna | 12 months > DPT > %: 96.7 Municipality of Bologna | 12 months > Polio > %: 96.7 Municipality of Bologna | 12 months > Hepatitis B > %: 95.9 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt index 2b382ae..24c1af8 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt @@ -26,16 +26,15 @@ UF coefficient (ml/mmHg/h) | Low-flux HD: 13 UF coefficient (ml/mmHg/h) | Low-flux HD: 18 UF coefficient (ml/mmHg/h) | Online HDF: 65 UF coefficient (ml/mmHg/h) | Online HDF: 59 -In vitro clearance: # -Urea | Low-flux HD: 260 -Urea | Low-flux HD: 251 -Urea | Online HDF: 268 -Urea | Online HDF: 276 -Phosphate | Low-flux HD: 198 -Phosphate | Low-flux HD: 193 -Phosphate | Online HDF: 229 -Phosphate | Online HDF: 239 -Vit B12 | Low-flux HD: 111 -Vit B12 | Low-flux HD: 118 -Vit B12 | Online HDF: 158 -Vit B12 | Online HDF: 175 \ No newline at end of file +In vitro clearance: # > Urea | Low-flux HD: 260 +In vitro clearance: # > Urea | Low-flux HD: 251 +In vitro clearance: # > Urea | Online HDF: 268 +In vitro clearance: # > Urea | Online HDF: 276 +In vitro clearance: # > Phosphate | Low-flux HD: 198 +In vitro clearance: # > Phosphate | Low-flux HD: 193 +In vitro clearance: # > Phosphate | Online HDF: 229 +In vitro clearance: # > Phosphate | Online HDF: 239 +In vitro clearance: # > Vit B12 | Low-flux HD: 111 +In vitro clearance: # > Vit B12 | Low-flux HD: 118 +In vitro clearance: # > Vit B12 | Online HDF: 158 +In vitro clearance: # > Vit B12 | Online HDF: 175 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt index a32c267..db0c647 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt @@ -1,52 +1,51 @@ -Adjusted for -Sex | Cognition at 7 > OR†: 1.42 -Sex | Cognition at 7 > (95% CI): (1.36 to 1.49) -Sex | Cognition at 9 > OR†: 1.50 -Sex | Cognition at 9 > (95% CI): (1.43 to 1.57) -Sex | Cognition at 11 > OR†: 1.55 -Sex | Cognition at 11 > (95% CI): (1.47 to 1.62) -Sex, Marital status at birth | Cognition at 7 > OR†: 1.42 -Sex, Marital status at birth | Cognition at 7 > (95% CI): (1.35 to 1.48) -Sex, Marital status at birth | Cognition at 9 > OR†: 1.49 -Sex, Marital status at birth | Cognition at 9 > (95% CI): (1.42 to 1.56) -Sex, Marital status at birth | Cognition at 11 > OR†: 1.54 -Sex, Marital status at birth | Cognition at 11 > (95% CI): (1.47 to 1.62) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > OR†: 1.34 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > (95% CI): (1.27 to 1.41) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > OR†: 1.42 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > (95% CI): (1.35 to 1.49) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > OR†: 1.48 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > (95% CI): (1.40 to 1.56) -Sex, Height & Weight at 1st medical exam | Cognition at 7 > OR†: 1.40 -Sex, Height & Weight at 1st medical exam | Cognition at 7 > (95% CI): (1.34 to 1.47) -Sex, Height & Weight at 1st medical exam | Cognition at 9 > OR†: 1.48 -Sex, Height & Weight at 1st medical exam | Cognition at 9 > (95% CI): (1.41 to 1.55) -Sex, Height & Weight at 1st medical exam | Cognition at 11 > OR†: 1.53 -Sex, Height & Weight at 1st medical exam | Cognition at 11 > (95% CI): (1.46 to 1.61) -Sex, Rutter B behavioral score | Cognition at 7 > OR†: 1.36 -Sex, Rutter B behavioral score | Cognition at 7 > (95% CI): (1.29 to 1.42) -Sex, Rutter B behavioral score | Cognition at 9 > OR†: 1.43 -Sex, Rutter B behavioral score | Cognition at 9 > (95% CI): (1.36 to 1.51) -Sex, Rutter B behavioral score | Cognition at 11 > OR†: 1.50 -Sex, Rutter B behavioral score | Cognition at 11 > (95% CI): (1.42 to 1.58) -Sex, All early life factors‡ | Cognition at 7 > OR†: 1.29 -Sex, All early life factors‡ | Cognition at 7 > (95% CI): (1.22 to 1.36) -Sex, All early life factors‡ | Cognition at 9 > OR†: 1.37 -Sex, All early life factors‡ | Cognition at 9 > (95% CI): (1.30 to 1.45) -Sex, All early life factors‡ | Cognition at 11 > OR†: 1.43 -Sex, All early life factors‡ | Cognition at 11 > (95% CI): (1.36 to 1.52) -Sex, Cognition at 7 | Cognition at 7 > (95% CI): - -Sex, Cognition at 7 | Cognition at 9 > OR†: 1.36 -Sex, Cognition at 7 | Cognition at 9 > (95% CI): (1.27 to 1.46) -Sex, Cognition at 7 | Cognition at 11 > OR†: 1.46 -Sex, Cognition at 7 | Cognition at 11 > (95% CI): (1.37 to 1.57) -Sex, Cognition at 9 | Cognition at 7 > OR†: 1.14 -Sex, Cognition at 9 | Cognition at 7 > (95% CI): (1.06 to 1.22) -Sex, Cognition at 9 | Cognition at 9 > (95% CI): - -Sex, Cognition at 9 | Cognition at 11 > OR†: 1.44 -Sex, Cognition at 9 | Cognition at 11 > (95% CI): (1.30 to 1.59) -Sex, Cognition at 11 | Cognition at 7 > OR†: 1.08 -Sex, Cognition at 11 | Cognition at 7 > (95% CI): (1.01 to 1.15) -Sex, Cognition at 11 | Cognition at 9 > OR†: 1.09 -Sex, Cognition at 11 | Cognition at 9 > (95% CI): (0.98 to 1.20) -Sex, Cognition at 11 | Cognition at 11 > (95% CI): - \ No newline at end of file +Adjusted for > Sex | Cognition at 7 > OR†: 1.42 +Adjusted for > Sex | Cognition at 7 > (95% CI): (1.36 to 1.49) +Adjusted for > Sex | Cognition at 9 > OR†: 1.50 +Adjusted for > Sex | Cognition at 9 > (95% CI): (1.43 to 1.57) +Adjusted for > Sex | Cognition at 11 > OR†: 1.55 +Adjusted for > Sex | Cognition at 11 > (95% CI): (1.47 to 1.62) +Adjusted for > Sex, Marital status at birth | Cognition at 7 > OR†: 1.42 +Adjusted for > Sex, Marital status at birth | Cognition at 7 > (95% CI): (1.35 to 1.48) +Adjusted for > Sex, Marital status at birth | Cognition at 9 > OR†: 1.49 +Adjusted for > Sex, Marital status at birth | Cognition at 9 > (95% CI): (1.42 to 1.56) +Adjusted for > Sex, Marital status at birth | Cognition at 11 > OR†: 1.54 +Adjusted for > Sex, Marital status at birth | Cognition at 11 > (95% CI): (1.47 to 1.62) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > OR†: 1.34 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > (95% CI): (1.27 to 1.41) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > OR†: 1.42 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > (95% CI): (1.35 to 1.49) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > OR†: 1.48 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > (95% CI): (1.40 to 1.56) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 7 > OR†: 1.40 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 7 > (95% CI): (1.34 to 1.47) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 9 > OR†: 1.48 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 9 > (95% CI): (1.41 to 1.55) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 11 > OR†: 1.53 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 11 > (95% CI): (1.46 to 1.61) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 7 > OR†: 1.36 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 7 > (95% CI): (1.29 to 1.42) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 9 > OR†: 1.43 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 9 > (95% CI): (1.36 to 1.51) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 11 > OR†: 1.50 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 11 > (95% CI): (1.42 to 1.58) +Adjusted for > Sex, All early life factors‡ | Cognition at 7 > OR†: 1.29 +Adjusted for > Sex, All early life factors‡ | Cognition at 7 > (95% CI): (1.22 to 1.36) +Adjusted for > Sex, All early life factors‡ | Cognition at 9 > OR†: 1.37 +Adjusted for > Sex, All early life factors‡ | Cognition at 9 > (95% CI): (1.30 to 1.45) +Adjusted for > Sex, All early life factors‡ | Cognition at 11 > OR†: 1.43 +Adjusted for > Sex, All early life factors‡ | Cognition at 11 > (95% CI): (1.36 to 1.52) +Adjusted for > Sex, Cognition at 7 | Cognition at 7 > (95% CI): - +Adjusted for > Sex, Cognition at 7 | Cognition at 9 > OR†: 1.36 +Adjusted for > Sex, Cognition at 7 | Cognition at 9 > (95% CI): (1.27 to 1.46) +Adjusted for > Sex, Cognition at 7 | Cognition at 11 > OR†: 1.46 +Adjusted for > Sex, Cognition at 7 | Cognition at 11 > (95% CI): (1.37 to 1.57) +Adjusted for > Sex, Cognition at 9 | Cognition at 7 > OR†: 1.14 +Adjusted for > Sex, Cognition at 9 | Cognition at 7 > (95% CI): (1.06 to 1.22) +Adjusted for > Sex, Cognition at 9 | Cognition at 9 > (95% CI): - +Adjusted for > Sex, Cognition at 9 | Cognition at 11 > OR†: 1.44 +Adjusted for > Sex, Cognition at 9 | Cognition at 11 > (95% CI): (1.30 to 1.59) +Adjusted for > Sex, Cognition at 11 | Cognition at 7 > OR†: 1.08 +Adjusted for > Sex, Cognition at 11 | Cognition at 7 > (95% CI): (1.01 to 1.15) +Adjusted for > Sex, Cognition at 11 | Cognition at 9 > OR†: 1.09 +Adjusted for > Sex, Cognition at 11 | Cognition at 9 > (95% CI): (0.98 to 1.20) +Adjusted for > Sex, Cognition at 11 | Cognition at 11 > (95% CI): - \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt index bf8289d..4cbb03e 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt @@ -1,74 +1,70 @@ -24 months -vaccine against -pertussis | 1998 > BO > %: 95.7 -pertussis | 1998 > ER > %: 96.8 -pertussis | 1999 > BO > %: 94.2 -pertussis | 1999 > ER > %: 96.1 -pertussis | 2000 > BO > %: 95.1 -pertussis | 2000 > ER > %: 96.7 -pertussis | 2001 > BO > %: 94.9 -pertussis | 2001 > ER > %: 96.8 -pertussis | 2002 > BO > %: 94.8 -pertussis | 2002 > ER > %: 96.8 -H. influenzae | 1998 > BO > %: 41.8 -H. influenzae | 1998 > ER > %: 50.6 -H. influenzae | 1999 > BO > %: 45.0 -H. influenzae | 1999 > ER > %: 66.8 -H. influenzae | 2000 > BO > %: 65.9 -H. influenzae | 2000 > ER > %: 81.0 -H. influenzae | 2001 > BO > %: 86.9 -H. influenzae | 2001 > ER > %: 90.6 -H. influenzae | 2002 > BO > %: 93.3 -H. influenzae | 2002 > ER > %: 95.2 -measles | 1998 > BO > %: 79.3 -measles | 1998 > ER > %: 88.2 -measles | 1999 > BO > %: 82.4 -measles | 1999 > ER > %: 89.1 -measles | 2000 > BO > %: 83.5 -measles | 2000 > ER > %: 90.4 -measles | 2001 > BO > %: 86.4 -measles | 2001 > ER > %: 90.7 -measles | 2002 > BO > %: 90.2 -measles | 2002 > ER > %: 92.3 -mumps | 1998 > BO > %: - -mumps | 1998 > ER > %: - -mumps | 1999 > BO > %: 78.8 -mumps | 1999 > ER > %: 84.2 -mumps | 2000 > BO > %: 83.3 -mumps | 2000 > ER > %: 89.4 -mumps | 2001 > BO > %: 85.1 -mumps | 2001 > ER > %: 90.1 -mumps | 2002 > BO > %: 88.8 -mumps | 2002 > ER > %: 91.7 -rubella | 1998 > BO > %: 77.2* -rubella | 1998 > ER > %: 85.2* -rubella | 1999 > BO > %: 78.6 -rubella | 1999 > ER > %: 88.0 -rubella | 2000 > BO > %: 83.4 -rubella | 2000 > ER > %: 89.4 -rubella | 2001 > BO > %: 85.6 -rubella | 2001 > ER > %: 90.1 -rubella | 2002 > BO > %: 88.8 -rubella | 2002 > ER > %: 91.7 -13 years -vaccine against -measles | 1998 > BO > %: 75.1 -measles | 1998 > ER > %: 83.8 -measles | 1999 > BO > %: 72.5 -measles | 1999 > ER > %: 89.1 -measles | 2000 > BO > %: 85.8 -measles | 2000 > ER > %: 84.9 -measles | 2001 > BO > %: 90.1 -measles | 2001 > ER > %: 87.4 -measles | 2002 > BO > %: 92.6 -measles | 2002 > ER > %: 91.3 -rubella | 1998 > BO > %: 84.7* -rubella | 1998 > ER > %: 85.2* -rubella | 1999 > BO > %: 49.9 -rubella | 1999 > ER > %: 60.8 -rubella | 2000 > BO > %: 72.6 -rubella | 2000 > ER > %: 66.3 -rubella | 2001 > BO > %: 76.1 -rubella | 2001 > ER > %: 73.4 -rubella | 2002 > BO > %: 84.2 -rubella | 2002 > ER > %: 80.6 \ No newline at end of file +24 months > vaccine against > pertussis | 1998 > BO > %: 95.7 +24 months > vaccine against > pertussis | 1998 > ER > %: 96.8 +24 months > vaccine against > pertussis | 1999 > BO > %: 94.2 +24 months > vaccine against > pertussis | 1999 > ER > %: 96.1 +24 months > vaccine against > pertussis | 2000 > BO > %: 95.1 +24 months > vaccine against > pertussis | 2000 > ER > %: 96.7 +24 months > vaccine against > pertussis | 2001 > BO > %: 94.9 +24 months > vaccine against > pertussis | 2001 > ER > %: 96.8 +24 months > vaccine against > pertussis | 2002 > BO > %: 94.8 +24 months > vaccine against > pertussis | 2002 > ER > %: 96.8 +24 months > vaccine against > H. influenzae | 1998 > BO > %: 41.8 +24 months > vaccine against > H. influenzae | 1998 > ER > %: 50.6 +24 months > vaccine against > H. influenzae | 1999 > BO > %: 45.0 +24 months > vaccine against > H. influenzae | 1999 > ER > %: 66.8 +24 months > vaccine against > H. influenzae | 2000 > BO > %: 65.9 +24 months > vaccine against > H. influenzae | 2000 > ER > %: 81.0 +24 months > vaccine against > H. influenzae | 2001 > BO > %: 86.9 +24 months > vaccine against > H. influenzae | 2001 > ER > %: 90.6 +24 months > vaccine against > H. influenzae | 2002 > BO > %: 93.3 +24 months > vaccine against > H. influenzae | 2002 > ER > %: 95.2 +24 months > vaccine against > measles | 1998 > BO > %: 79.3 +24 months > vaccine against > measles | 1998 > ER > %: 88.2 +24 months > vaccine against > measles | 1999 > BO > %: 82.4 +24 months > vaccine against > measles | 1999 > ER > %: 89.1 +24 months > vaccine against > measles | 2000 > BO > %: 83.5 +24 months > vaccine against > measles | 2000 > ER > %: 90.4 +24 months > vaccine against > measles | 2001 > BO > %: 86.4 +24 months > vaccine against > measles | 2001 > ER > %: 90.7 +24 months > vaccine against > measles | 2002 > BO > %: 90.2 +24 months > vaccine against > measles | 2002 > ER > %: 92.3 +24 months > vaccine against > mumps | 1998 > BO > %: - +24 months > vaccine against > mumps | 1998 > ER > %: - +24 months > vaccine against > mumps | 1999 > BO > %: 78.8 +24 months > vaccine against > mumps | 1999 > ER > %: 84.2 +24 months > vaccine against > mumps | 2000 > BO > %: 83.3 +24 months > vaccine against > mumps | 2000 > ER > %: 89.4 +24 months > vaccine against > mumps | 2001 > BO > %: 85.1 +24 months > vaccine against > mumps | 2001 > ER > %: 90.1 +24 months > vaccine against > mumps | 2002 > BO > %: 88.8 +24 months > vaccine against > mumps | 2002 > ER > %: 91.7 +24 months > vaccine against > rubella | 1998 > BO > %: 77.2* +24 months > vaccine against > rubella | 1998 > ER > %: 85.2* +24 months > vaccine against > rubella | 1999 > BO > %: 78.6 +24 months > vaccine against > rubella | 1999 > ER > %: 88.0 +24 months > vaccine against > rubella | 2000 > BO > %: 83.4 +24 months > vaccine against > rubella | 2000 > ER > %: 89.4 +24 months > vaccine against > rubella | 2001 > BO > %: 85.6 +24 months > vaccine against > rubella | 2001 > ER > %: 90.1 +24 months > vaccine against > rubella | 2002 > BO > %: 88.8 +24 months > vaccine against > rubella | 2002 > ER > %: 91.7 +13 years > vaccine against > measles | 1998 > BO > %: 75.1 +13 years > vaccine against > measles | 1998 > ER > %: 83.8 +13 years > vaccine against > measles | 1999 > BO > %: 72.5 +13 years > vaccine against > measles | 1999 > ER > %: 89.1 +13 years > vaccine against > measles | 2000 > BO > %: 85.8 +13 years > vaccine against > measles | 2000 > ER > %: 84.9 +13 years > vaccine against > measles | 2001 > BO > %: 90.1 +13 years > vaccine against > measles | 2001 > ER > %: 87.4 +13 years > vaccine against > measles | 2002 > BO > %: 92.6 +13 years > vaccine against > measles | 2002 > ER > %: 91.3 +13 years > vaccine against > rubella | 1998 > BO > %: 84.7* +13 years > vaccine against > rubella | 1998 > ER > %: 85.2* +13 years > vaccine against > rubella | 1999 > BO > %: 49.9 +13 years > vaccine against > rubella | 1999 > ER > %: 60.8 +13 years > vaccine against > rubella | 2000 > BO > %: 72.6 +13 years > vaccine against > rubella | 2000 > ER > %: 66.3 +13 years > vaccine against > rubella | 2001 > BO > %: 76.1 +13 years > vaccine against > rubella | 2001 > ER > %: 73.4 +13 years > vaccine against > rubella | 2002 > BO > %: 84.2 +13 years > vaccine against > rubella | 2002 > ER > %: 80.6 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt index 4d6af73..c001fd5 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt @@ -1,66 +1,63 @@ -Asthma -No | Case (n = 158) > n: 96 -No | Case (n = 158) > %: 60.7 -No | Control (n = 171) > n: 126 -No | Control (n = 171) > %: 73.6 -No | p-value: 0.007 -Father | Case (n = 158) > n: 12 -Father | Case (n = 158) > %: 7.6 -Father | Control (n = 171) > n: 7 -Father | Control (n = 171) > %: 4.1 -Mother | Case (n = 158) > n: 12 -Mother | Case (n = 158) > %: 7.6 -Mother | Control (n = 171) > n: 7 -Mother | Control (n = 171) > %: 4.1 -More than one in the family | Case (n = 158) > n: 18 -More than one in the family | Case (n = 158) > %: 11.4 -More than one in the family | Control (n = 171) > n: 5 -More than one in the family | Control (n = 171) > %: 2.9 -Sibling | Case (n = 158) > n: 20 -Sibling | Case (n = 158) > %: 12.6 -Sibling | Control (n = 171) > n: 26 -Sibling | Control (n = 171) > %: 15.2 -Allergic rhinitis -No | Case (n = 158) > n: 67 -No | Case (n = 158) > %: 42.4 -No | Control (n = 171) > n: 91 -No | Control (n = 171) > %: 53.2 -No | p-value: 0.10 -Father | Case (n = 158) > n: 16 -Father | Case (n = 158) > %: 10.1 -Father | Control (n = 171) > n: 20 -Father | Control (n = 171) > %: 11.7 -Mother | Case (n = 158) > n: 29 -Mother | Case (n = 158) > %: 18.4 -Mother | Control (n = 171) > n: 17 -Mother | Control (n = 171) > %: 9.9 -More than one in the family | Case (n = 158) > n: 34 -More than one in the family | Case (n = 158) > %: 21.5 -More than one in the family | Control (n = 171) > n: 28 -More than one in the family | Control (n = 171) > %: 16.3 -Sibling | Case (n = 158) > n: 12 -Sibling | Case (n = 158) > %: 7.6 -Sibling | Control (n = 171) > n: 15 -Sibling | Control (n = 171) > %: 8.8 -Eczema as a Child -No | Case (n = 158) > n: 80 -No | Case (n = 158) > %: 50.6 -No | Control (n = 171) > n: 87 -No | Control (n = 171) > %: 50.8 -No | p-value: 0.97 -Father | Case (n = 158) > n: 8 -Father | Case (n = 158) > %: 5.0 -Father | Control (n = 171) > n: 6 -Father | Control (n = 171) > %: 2.9 -Mother | Case (n = 158) > n: 15 -Mother | Case (n = 158) > %: 9.5 -Mother | Control (n = 171) > n: 17 -Mother | Control (n = 171) > %: 9.9 -More than one in the family | Case (n = 158) > n: 22 -More than one in the family | Case (n = 158) > %: 13.9 -More than one in the family | Control (n = 171) > n: 25 -More than one in the family | Control (n = 171) > %: 14.6 -Sibling | Case (n = 158) > n: 33 -Sibling | Case (n = 158) > %: 20.8 -Sibling | Control (n = 171) > n: 36 -Sibling | Control (n = 171) > %: 21.0 \ No newline at end of file +Asthma > No | Case (n = 158) > n: 96 +Asthma > No | Case (n = 158) > %: 60.7 +Asthma > No | Control (n = 171) > n: 126 +Asthma > No | Control (n = 171) > %: 73.6 +Asthma > No | p-value: 0.007 +Asthma > Father | Case (n = 158) > n: 12 +Asthma > Father | Case (n = 158) > %: 7.6 +Asthma > Father | Control (n = 171) > n: 7 +Asthma > Father | Control (n = 171) > %: 4.1 +Asthma > Mother | Case (n = 158) > n: 12 +Asthma > Mother | Case (n = 158) > %: 7.6 +Asthma > Mother | Control (n = 171) > n: 7 +Asthma > Mother | Control (n = 171) > %: 4.1 +Asthma > More than one in the family | Case (n = 158) > n: 18 +Asthma > More than one in the family | Case (n = 158) > %: 11.4 +Asthma > More than one in the family | Control (n = 171) > n: 5 +Asthma > More than one in the family | Control (n = 171) > %: 2.9 +Asthma > Sibling | Case (n = 158) > n: 20 +Asthma > Sibling | Case (n = 158) > %: 12.6 +Asthma > Sibling | Control (n = 171) > n: 26 +Asthma > Sibling | Control (n = 171) > %: 15.2 +Allergic rhinitis > No | Case (n = 158) > n: 67 +Allergic rhinitis > No | Case (n = 158) > %: 42.4 +Allergic rhinitis > No | Control (n = 171) > n: 91 +Allergic rhinitis > No | Control (n = 171) > %: 53.2 +Allergic rhinitis > No | p-value: 0.10 +Allergic rhinitis > Father | Case (n = 158) > n: 16 +Allergic rhinitis > Father | Case (n = 158) > %: 10.1 +Allergic rhinitis > Father | Control (n = 171) > n: 20 +Allergic rhinitis > Father | Control (n = 171) > %: 11.7 +Allergic rhinitis > Mother | Case (n = 158) > n: 29 +Allergic rhinitis > Mother | Case (n = 158) > %: 18.4 +Allergic rhinitis > Mother | Control (n = 171) > n: 17 +Allergic rhinitis > Mother | Control (n = 171) > %: 9.9 +Allergic rhinitis > More than one in the family | Case (n = 158) > n: 34 +Allergic rhinitis > More than one in the family | Case (n = 158) > %: 21.5 +Allergic rhinitis > More than one in the family | Control (n = 171) > n: 28 +Allergic rhinitis > More than one in the family | Control (n = 171) > %: 16.3 +Allergic rhinitis > Sibling | Case (n = 158) > n: 12 +Allergic rhinitis > Sibling | Case (n = 158) > %: 7.6 +Allergic rhinitis > Sibling | Control (n = 171) > n: 15 +Allergic rhinitis > Sibling | Control (n = 171) > %: 8.8 +Eczema as a Child > No | Case (n = 158) > n: 80 +Eczema as a Child > No | Case (n = 158) > %: 50.6 +Eczema as a Child > No | Control (n = 171) > n: 87 +Eczema as a Child > No | Control (n = 171) > %: 50.8 +Eczema as a Child > No | p-value: 0.97 +Eczema as a Child > Father | Case (n = 158) > n: 8 +Eczema as a Child > Father | Case (n = 158) > %: 5.0 +Eczema as a Child > Father | Control (n = 171) > n: 6 +Eczema as a Child > Father | Control (n = 171) > %: 2.9 +Eczema as a Child > Mother | Case (n = 158) > n: 15 +Eczema as a Child > Mother | Case (n = 158) > %: 9.5 +Eczema as a Child > Mother | Control (n = 171) > n: 17 +Eczema as a Child > Mother | Control (n = 171) > %: 9.9 +Eczema as a Child > More than one in the family | Case (n = 158) > n: 22 +Eczema as a Child > More than one in the family | Case (n = 158) > %: 13.9 +Eczema as a Child > More than one in the family | Control (n = 171) > n: 25 +Eczema as a Child > More than one in the family | Control (n = 171) > %: 14.6 +Eczema as a Child > Sibling | Case (n = 158) > n: 33 +Eczema as a Child > Sibling | Case (n = 158) > %: 20.8 +Eczema as a Child > Sibling | Control (n = 171) > n: 36 +Eczema as a Child > Sibling | Control (n = 171) > %: 21.0 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt index 3b53051..9696e13 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt @@ -1,73 +1,71 @@ -Knows someone with tuberculosis -Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 305 -Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 63.0 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 179 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.0 -Yes | Crude OR: 1.00 -Yes | 95% CI: - -Yes | P value: - -No | Total delay in treatment > Unacceptable (> 60 days) > N: 375 -No | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 -No | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 -No | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 -No | Crude OR: 0.93 -No | 95% CI: 0.72 – 1.19 -No | P value: 0.5782 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 680 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 415 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - -Recent contact with someone with tuberculosis | P value: 0.8554 -< 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 151 -< 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 63.4 -< 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 87 -< 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.6 -< 1 year | Crude OR: 1.00 -< 1 year | 95% CI: - -< 1 year | P value: - -≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 128 -≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 61.8 -≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 79 -≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.2 -≥ 1 year | Crude OR: 0.93 -≥ 1 year | 95% CI: 0.63 – 1.37 -≥ 1 year | P value: 0.7263 -Not known | Total delay in treatment > Unacceptable (> 60 days) > N: 375 -Not known | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 -Not known | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 -Not known | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 -Not known | Crude OR: 0.91 -Not known | 95% CI: 0.67 – 1.24 -Not known | P value: 0.5769 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 654 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 402 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - -Household contact with a case of tuberculosis -Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 104 -Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 62.7 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 62 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.3 -Yes | Crude OR: 1.00 -Yes | 95% CI: - -Yes | P value: - -No | Total delay in treatment > Unacceptable (> 60 days) > N: 198 -No | Total delay in treatment > Unacceptable (> 60 days) > %: 63.1 -No | Total delay in treatment > Acceptable (≤ 60 days) > N: 116 -No | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.9 -No | Crude OR: 1.01 -No | 95% CI: 0.68 – 1.50 -No | P value: 0.9301 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 302 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 178 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - \ No newline at end of file +Knows someone with tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 305 +Knows someone with tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 63.0 +Knows someone with tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 179 +Knows someone with tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.0 +Knows someone with tuberculosis > Yes | Crude OR: 1.00 +Knows someone with tuberculosis > Yes | 95% CI: - +Knows someone with tuberculosis > Yes | P value: - +Knows someone with tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > N: 375 +Knows someone with tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 +Knows someone with tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 +Knows someone with tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 +Knows someone with tuberculosis > No | Crude OR: 0.93 +Knows someone with tuberculosis > No | 95% CI: 0.72 – 1.19 +Knows someone with tuberculosis > No | P value: 0.5782 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 680 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 415 +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Knows someone with tuberculosis > Total | Crude OR: - +Knows someone with tuberculosis > Total | 95% CI: - +Knows someone with tuberculosis > Total | P value: - +Knows someone with tuberculosis > Recent contact with someone with tuberculosis | P value: 0.8554 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 151 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 63.4 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 87 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.6 +Knows someone with tuberculosis > < 1 year | Crude OR: 1.00 +Knows someone with tuberculosis > < 1 year | 95% CI: - +Knows someone with tuberculosis > < 1 year | P value: - +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 128 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 61.8 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 79 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.2 +Knows someone with tuberculosis > ≥ 1 year | Crude OR: 0.93 +Knows someone with tuberculosis > ≥ 1 year | 95% CI: 0.63 – 1.37 +Knows someone with tuberculosis > ≥ 1 year | P value: 0.7263 +Knows someone with tuberculosis > Not known | Total delay in treatment > Unacceptable (> 60 days) > N: 375 +Knows someone with tuberculosis > Not known | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 +Knows someone with tuberculosis > Not known | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 +Knows someone with tuberculosis > Not known | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 +Knows someone with tuberculosis > Not known | Crude OR: 0.91 +Knows someone with tuberculosis > Not known | 95% CI: 0.67 – 1.24 +Knows someone with tuberculosis > Not known | P value: 0.5769 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 654 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 402 +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Knows someone with tuberculosis > Total | Crude OR: - +Knows someone with tuberculosis > Total | 95% CI: - +Knows someone with tuberculosis > Total | P value: - +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 104 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 62.7 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 62 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.3 +Household contact with a case of tuberculosis > Yes | Crude OR: 1.00 +Household contact with a case of tuberculosis > Yes | 95% CI: - +Household contact with a case of tuberculosis > Yes | P value: - +Household contact with a case of tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > N: 198 +Household contact with a case of tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > %: 63.1 +Household contact with a case of tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > N: 116 +Household contact with a case of tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.9 +Household contact with a case of tuberculosis > No | Crude OR: 1.01 +Household contact with a case of tuberculosis > No | 95% CI: 0.68 – 1.50 +Household contact with a case of tuberculosis > No | P value: 0.9301 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 302 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Household contact with a case of tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 178 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Household contact with a case of tuberculosis > Total | Crude OR: - +Household contact with a case of tuberculosis > Total | 95% CI: - +Household contact with a case of tuberculosis > Total | P value: - \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt index bce8fa9..0972bab 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt @@ -1,52 +1,48 @@ -Fibroblasts -Total > OA | Nucleotides sequenced: 18489 -Total > OA | Number of mutations > Initial: 38 -Total > OA | Number of mutations > Published polymorphisms removed: 20 -Total > OA | Total mutational burden (mutations/kbp) > Initial: 2.055 -Total > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.082 -Total > RA | Nucleotides sequenced: 30503 -Total > RA | Number of mutations > Initial: 101 -Total > RA | Number of mutations > Published polymorphisms removed: 65 -Total > RA | Total mutational burden (mutations/kbp) > Initial: 3.311 -Total > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.131 -Total > RA | OA vs RA a > Initial: ρ = 0.01 -Total > RA | OA vs RA a > Published Polymorphisms removed: ρ = 6.9 × 10 -3 -Tissue -Total > OA | Nucleotides sequenced: 37145 -Total > OA | Number of mutations > Initial: 67 -Total > OA | Number of mutations > Published polymorphisms removed: 40 -Total > OA | Total mutational burden (mutations/kbp) > Initial: 1.804 -Total > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.077 -Total > RA | Nucleotides sequenced: 17663 -Total > RA | Number of mutations > Initial: 60 -Total > RA | Number of mutations > Published polymorphisms removed: 42 -Total > RA | Total mutational burden (mutations/kbp) > Initial: 3.397 -Total > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.378 -Total > RA | OA vs RA a > Initial: ρ = 4 × 10 -4 -Total > RA | OA vs RA a > Published Polymorphisms removed: ρ = 5.1 × 10 -4 -Fibroblasts -Expressed > OA | Nucleotides sequenced: 6956 -Expressed > OA | Number of mutations > Initial: 12 -Expressed > OA | Number of mutations > Published polymorphisms removed: 7 -Expressed > OA | Total mutational burden (mutations/kbp) > Initial: 1.725 -Expressed > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.006 -Expressed > RA | Nucleotides sequenced: 12394 -Expressed > RA | Number of mutations > Initial: 28 -Expressed > RA | Number of mutations > Published polymorphisms removed: 26 -Expressed > RA | Total mutational burden (mutations/kbp) > Initial: 2.259 -Expressed > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.098 -Expressed > RA | OA vs RA a > Initial: ρ = 0.5 -Expressed > RA | OA vs RA a > Published Polymorphisms removed: ρ = 0.10 -Tissue -Expressed > OA | Nucleotides sequenced: 15805 -Expressed > OA | Number of mutations > Initial: 10 -Expressed > OA | Number of mutations > Published polymorphisms removed: 10 -Expressed > OA | Total mutational burden (mutations/kbp) > Initial: 0.633 -Expressed > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 0.633 -Expressed > RA | Nucleotides sequenced: 6397 -Expressed > RA | Number of mutations > Initial: 16 -Expressed > RA | Number of mutations > Published polymorphisms removed: 14 -Expressed > RA | Total mutational burden (mutations/kbp) > Initial: 2.501 -Expressed > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.189 -Expressed > RA | OA vs RA a > Initial: ρ = 6 × 10 -4 -Expressed > RA | OA vs RA a > Published Polymorphisms removed: ρ = 2.7 × 10 -3 \ No newline at end of file +Total > Fibroblasts > OA | Nucleotides sequenced: 18489 +Total > Fibroblasts > OA | Number of mutations > Initial: 38 +Total > Fibroblasts > OA | Number of mutations > Published polymorphisms removed: 20 +Total > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Initial: 2.055 +Total > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.082 +Total > Fibroblasts > RA | Nucleotides sequenced: 30503 +Total > Fibroblasts > RA | Number of mutations > Initial: 101 +Total > Fibroblasts > RA | Number of mutations > Published polymorphisms removed: 65 +Total > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Initial: 3.311 +Total > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.131 +Total > Fibroblasts > RA | OA vs RA a > Initial: ρ = 0.01 +Total > Fibroblasts > RA | OA vs RA a > Published Polymorphisms removed: ρ = 6.9 × 10 -3 +Total > Tissue > OA | Nucleotides sequenced: 37145 +Total > Tissue > OA | Number of mutations > Initial: 67 +Total > Tissue > OA | Number of mutations > Published polymorphisms removed: 40 +Total > Tissue > OA | Total mutational burden (mutations/kbp) > Initial: 1.804 +Total > Tissue > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.077 +Total > Tissue > RA | Nucleotides sequenced: 17663 +Total > Tissue > RA | Number of mutations > Initial: 60 +Total > Tissue > RA | Number of mutations > Published polymorphisms removed: 42 +Total > Tissue > RA | Total mutational burden (mutations/kbp) > Initial: 3.397 +Total > Tissue > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.378 +Total > Tissue > RA | OA vs RA a > Initial: ρ = 4 × 10 -4 +Total > Tissue > RA | OA vs RA a > Published Polymorphisms removed: ρ = 5.1 × 10 -4 +Expressed > Fibroblasts > OA | Nucleotides sequenced: 6956 +Expressed > Fibroblasts > OA | Number of mutations > Initial: 12 +Expressed > Fibroblasts > OA | Number of mutations > Published polymorphisms removed: 7 +Expressed > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Initial: 1.725 +Expressed > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.006 +Expressed > Fibroblasts > RA | Nucleotides sequenced: 12394 +Expressed > Fibroblasts > RA | Number of mutations > Initial: 28 +Expressed > Fibroblasts > RA | Number of mutations > Published polymorphisms removed: 26 +Expressed > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Initial: 2.259 +Expressed > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.098 +Expressed > Fibroblasts > RA | OA vs RA a > Initial: ρ = 0.5 +Expressed > Fibroblasts > RA | OA vs RA a > Published Polymorphisms removed: ρ = 0.10 +Expressed > Tissue > OA | Nucleotides sequenced: 15805 +Expressed > Tissue > OA | Number of mutations > Initial: 10 +Expressed > Tissue > OA | Number of mutations > Published polymorphisms removed: 10 +Expressed > Tissue > OA | Total mutational burden (mutations/kbp) > Initial: 0.633 +Expressed > Tissue > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 0.633 +Expressed > Tissue > RA | Nucleotides sequenced: 6397 +Expressed > Tissue > RA | Number of mutations > Initial: 16 +Expressed > Tissue > RA | Number of mutations > Published polymorphisms removed: 14 +Expressed > Tissue > RA | Total mutational burden (mutations/kbp) > Initial: 2.501 +Expressed > Tissue > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.189 +Expressed > Tissue > RA | OA vs RA a > Initial: ρ = 6 × 10 -4 +Expressed > Tissue > RA | OA vs RA a > Published Polymorphisms removed: ρ = 2.7 × 10 -3 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt index c55a7fc..c7895e1 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt @@ -1,34 +1,32 @@ -Increase, mm 2 -Medial | Total: 36.8 ± 70.7 -Medial | P: <0.001 -Medial | Crude analysis > Men: 38.3 ± 62.6 -Medial | Crude analysis > Women: 35.7 ± 76.1 -Medial | Crude analysis > P a: 0.85 -Medial | Adjusted analysis > Men: 70.8 ± 12.3 -Medial | Adjusted analysis > Women: 13.5 ± 9.6 -Medial | Adjusted analysis > P b: 0.002 -Lateral | Total: 19.1 ± 60.1 -Lateral | P: 0.004 -Lateral | Crude analysis > Men: 16.5 ± 83.9 -Lateral | Crude analysis > Women: 20.4 ± 45.1 -Lateral | Crude analysis > P a: 0.77 -Lateral | Adjusted analysis > Men: 17.2 ± 13.3 -Lateral | Adjusted analysis > Women: 20.1 ± 8.5 -Lateral | Adjusted analysis > P b: 0.87 -Change % -Medial | Total: 2.2 ± 6.9 -Medial | P: <0.001 -Medial | Crude analysis > Men: 1.6 ± 2.8 -Medial | Crude analysis > Women: 2.6 ± 8.7 -Medial | Crude analysis > P a: 0.49 -Medial | Adjusted analysis > Men: 5.4 ± 1.1 -Medial | Adjusted analysis > Women: 0.004 ± 0.9 -Medial | Adjusted analysis > P b: 0.001 -Lateral | Total: 1.5 ± 4.3 -Lateral | P: 0.004 -Lateral | Crude analysis > Men: 1.3 ± 5.8 -Lateral | Crude analysis > Women: 1.6 ± 3.4 -Lateral | Crude analysis > P a: 0.79 -Lateral | Adjusted analysis > Men: 1.6 ± 0.9 -Lateral | Adjusted analysis > Women: 1.5 ± 0.6 -Lateral | Adjusted analysis > P b: 0.95 \ No newline at end of file +Increase, mm 2 > Medial | Total: 36.8 ± 70.7 +Increase, mm 2 > Medial | P: <0.001 +Increase, mm 2 > Medial | Crude analysis > Men: 38.3 ± 62.6 +Increase, mm 2 > Medial | Crude analysis > Women: 35.7 ± 76.1 +Increase, mm 2 > Medial | Crude analysis > P a: 0.85 +Increase, mm 2 > Medial | Adjusted analysis > Men: 70.8 ± 12.3 +Increase, mm 2 > Medial | Adjusted analysis > Women: 13.5 ± 9.6 +Increase, mm 2 > Medial | Adjusted analysis > P b: 0.002 +Increase, mm 2 > Lateral | Total: 19.1 ± 60.1 +Increase, mm 2 > Lateral | P: 0.004 +Increase, mm 2 > Lateral | Crude analysis > Men: 16.5 ± 83.9 +Increase, mm 2 > Lateral | Crude analysis > Women: 20.4 ± 45.1 +Increase, mm 2 > Lateral | Crude analysis > P a: 0.77 +Increase, mm 2 > Lateral | Adjusted analysis > Men: 17.2 ± 13.3 +Increase, mm 2 > Lateral | Adjusted analysis > Women: 20.1 ± 8.5 +Increase, mm 2 > Lateral | Adjusted analysis > P b: 0.87 +Change % > Medial | Total: 2.2 ± 6.9 +Change % > Medial | P: <0.001 +Change % > Medial | Crude analysis > Men: 1.6 ± 2.8 +Change % > Medial | Crude analysis > Women: 2.6 ± 8.7 +Change % > Medial | Crude analysis > P a: 0.49 +Change % > Medial | Adjusted analysis > Men: 5.4 ± 1.1 +Change % > Medial | Adjusted analysis > Women: 0.004 ± 0.9 +Change % > Medial | Adjusted analysis > P b: 0.001 +Change % > Lateral | Total: 1.5 ± 4.3 +Change % > Lateral | P: 0.004 +Change % > Lateral | Crude analysis > Men: 1.3 ± 5.8 +Change % > Lateral | Crude analysis > Women: 1.6 ± 3.4 +Change % > Lateral | Crude analysis > P a: 0.79 +Change % > Lateral | Adjusted analysis > Men: 1.6 ± 0.9 +Change % > Lateral | Adjusted analysis > Women: 1.5 ± 0.6 +Change % > Lateral | Adjusted analysis > P b: 0.95 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt index 965d7f3..0d2eeda 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt @@ -22,86 +22,84 @@ Number of deliveries (live and stillbirths) (mean ± SEM) | WELL-HART ( n = 105) Number of deliveries (live and stillbirths) (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 4.1 ± 0.5 Number of deliveries (live and stillbirths) (mean ± SEM) | P *: 0.47 Number of deliveries (live and stillbirths) (mean ± SEM) | P †: 0.0001 -Race, n (%) -White, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 34 (59.7) -White, non-latina | EPAT ( n = 127) > ET ( n = 70): 40 (57.1) -White, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 12 (32.4) -White, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -White, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 14 (41.2) -Black, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 6 (10.5) -Black, non-latina | EPAT ( n = 127) > ET ( n = 70): 10 (14.3) -Black, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 4 (10.8) -Black, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 10 (29.4) -Black, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 5 (14.7) -Latina | EPAT ( n = 127) > Placebo ( n = 57): 10 (17.5) -Latina | EPAT ( n = 127) > ET ( n = 70): 13 (18.6) -Latina | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) -Latina | WELL-HART ( n = 105) > ET ( n = 34): 9 (26.5) -Latina | WELL-HART ( n = 105) > EPT ( n = 34): 11 (32.4) -Asian or Pacific Islander | EPAT ( n = 127) > Placebo ( n = 57): 7 (12.3) -Asian or Pacific Islander | EPAT ( n = 127) > ET ( n = 70): 7 (10.0) -Asian or Pacific Islander | P: 0.91 -Asian or Pacific Islander | WELL-HART ( n = 105) > Placebo ( n = 37): 1 (2.7) -Asian or Pacific Islander | WELL-HART ( n = 105) > ET ( n = 34): 8 (23.5) -Asian or Pacific Islander | WELL-HART ( n = 105) > EPT ( n = 34): 4 (11.8) -Asian or Pacific Islander | P *: 0.01 ‡ -Asian or Pacific Islander | P †: 0.0005 -Education, n (%) -High school graduate or less | EPAT ( n = 127) > Placebo ( n = 57): 8 (14.0) -High school graduate or less | EPAT ( n = 127) > ET ( n = 70): 9 (12.9) -High school graduate or less | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) -High school graduate or less | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) -High school graduate or less | WELL-HART ( n = 105) > EPT ( n = 34): 15 (44.1) -Trade or business school/some college | EPAT ( n = 127) > Placebo ( n = 57): 29 (50.9) -Trade or business school/some college | EPAT ( n = 127) > ET ( n = 70): 33 (48.6) -Trade or business school/some college | WELL-HART ( n = 105) > Placebo ( n = 37): 11 (29.7) -Trade or business school/some college | WELL-HART ( n = 105) > ET ( n = 34): 12 (35.3) -Trade or business school/some college | WELL-HART ( n = 105) > EPT ( n = 34): 13 (38.2) -Bachelor's degree or more | EPAT ( n = 127) > Placebo ( n = 57): 20 (35.1) -Bachelor's degree or more | EPAT ( n = 127) > ET ( n = 70): 27 (38.6) -Bachelor's degree or more | P: 0.92 -Bachelor's degree or more | WELL-HART ( n = 105) > Placebo ( n = 37): 6 (16.2) -Bachelor's degree or more | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -Bachelor's degree or more | WELL-HART ( n = 105) > EPT ( n = 34): 6 (17.7) -Bachelor's degree or more | P *: 0.90 -Bachelor's degree or more | P †: 0.0001 -Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > Placebo ( n = 57): 9 (15.8) -Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > ET ( n = 70): 6 (8.6) -Family history of breast cancer (first-degree relative), n (%) | P: 0.21 -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 2 (5.4) -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 3 (8.8) -Family history of breast cancer (first-degree relative), n (%) | P *: 0.14 ‡ -Family history of breast cancer (first-degree relative), n (%) | P †: 0.91 -Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 12.7 ± 0.2 -Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 12.6 ± 0.2 -Age at menarche, years (mean ± SEM) | P: 0.86 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 12.7 ± 0.3 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 12.8 ± 0.3 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 0.3 -Age at menarche, years (mean ± SEM) | P *: 0.32 -Age at menarche, years (mean ± SEM) | P †: 0.21 -Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > Placebo ( n = 57): 36 (63.2) -Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > ET ( n = 70): 42 (60.0) -Ever used postmenopausal hormones, n (%) | P: 0.72 -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 13 (35.1) -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 21 (61.8) -Ever used postmenopausal hormones, n (%) | P *: 0.08 -Ever used postmenopausal hormones, n (%) | P †: 0.02 -BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 28.7 ± 0.7 -BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 28.7 ± 0.7 -BMI, kg/m 2 (mean ± SEM) | P: 0.96 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 30.8 ± 1.0 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 31.4 ± 1.0 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 30.2 ± 1.1 -BMI, kg/m 2 (mean ± SEM) | P *: 0.73 -BMI, kg/m 2 (mean ± SEM) | P †: 0.007 -Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 17.8 ± 2.3 -Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 22.3 ± 1.9 -Mammographic density at baseline, % (mean ± SEM) | P: 0.13 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 7.9 ± 1.8 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 10.8 ± 2.1 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 2.3 -Mammographic density at baseline, % (mean ± SEM) | P *: 0.19 -Mammographic density at baseline, % (mean ± SEM) | P †: 0.0001 \ No newline at end of file +Race, n (%) > White, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 34 (59.7) +Race, n (%) > White, non-latina | EPAT ( n = 127) > ET ( n = 70): 40 (57.1) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 12 (32.4) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 14 (41.2) +Race, n (%) > Black, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 6 (10.5) +Race, n (%) > Black, non-latina | EPAT ( n = 127) > ET ( n = 70): 10 (14.3) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 4 (10.8) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 10 (29.4) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 5 (14.7) +Race, n (%) > Latina | EPAT ( n = 127) > Placebo ( n = 57): 10 (17.5) +Race, n (%) > Latina | EPAT ( n = 127) > ET ( n = 70): 13 (18.6) +Race, n (%) > Latina | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) +Race, n (%) > Latina | WELL-HART ( n = 105) > ET ( n = 34): 9 (26.5) +Race, n (%) > Latina | WELL-HART ( n = 105) > EPT ( n = 34): 11 (32.4) +Race, n (%) > Asian or Pacific Islander | EPAT ( n = 127) > Placebo ( n = 57): 7 (12.3) +Race, n (%) > Asian or Pacific Islander | EPAT ( n = 127) > ET ( n = 70): 7 (10.0) +Race, n (%) > Asian or Pacific Islander | P: 0.91 +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > Placebo ( n = 37): 1 (2.7) +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > ET ( n = 34): 8 (23.5) +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > EPT ( n = 34): 4 (11.8) +Race, n (%) > Asian or Pacific Islander | P *: 0.01 ‡ +Race, n (%) > Asian or Pacific Islander | P †: 0.0005 +Education, n (%) > High school graduate or less | EPAT ( n = 127) > Placebo ( n = 57): 8 (14.0) +Education, n (%) > High school graduate or less | EPAT ( n = 127) > ET ( n = 70): 9 (12.9) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > EPT ( n = 34): 15 (44.1) +Education, n (%) > Trade or business school/some college | EPAT ( n = 127) > Placebo ( n = 57): 29 (50.9) +Education, n (%) > Trade or business school/some college | EPAT ( n = 127) > ET ( n = 70): 33 (48.6) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > Placebo ( n = 37): 11 (29.7) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > ET ( n = 34): 12 (35.3) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > EPT ( n = 34): 13 (38.2) +Education, n (%) > Bachelor's degree or more | EPAT ( n = 127) > Placebo ( n = 57): 20 (35.1) +Education, n (%) > Bachelor's degree or more | EPAT ( n = 127) > ET ( n = 70): 27 (38.6) +Education, n (%) > Bachelor's degree or more | P: 0.92 +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > Placebo ( n = 37): 6 (16.2) +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > EPT ( n = 34): 6 (17.7) +Education, n (%) > Bachelor's degree or more | P *: 0.90 +Education, n (%) > Bachelor's degree or more | P †: 0.0001 +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > Placebo ( n = 57): 9 (15.8) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > ET ( n = 70): 6 (8.6) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P: 0.21 +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 2 (5.4) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 3 (8.8) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P *: 0.14 ‡ +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P †: 0.91 +Education, n (%) > Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 12.7 ± 0.2 +Education, n (%) > Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 12.6 ± 0.2 +Education, n (%) > Age at menarche, years (mean ± SEM) | P: 0.86 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 12.7 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 12.8 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | P *: 0.32 +Education, n (%) > Age at menarche, years (mean ± SEM) | P †: 0.21 +Education, n (%) > Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > Placebo ( n = 57): 36 (63.2) +Education, n (%) > Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > ET ( n = 70): 42 (60.0) +Education, n (%) > Ever used postmenopausal hormones, n (%) | P: 0.72 +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 13 (35.1) +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 21 (61.8) +Education, n (%) > Ever used postmenopausal hormones, n (%) | P *: 0.08 +Education, n (%) > Ever used postmenopausal hormones, n (%) | P †: 0.02 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 28.7 ± 0.7 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 28.7 ± 0.7 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P: 0.96 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 30.8 ± 1.0 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 31.4 ± 1.0 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 30.2 ± 1.1 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P *: 0.73 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P †: 0.007 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 17.8 ± 2.3 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 22.3 ± 1.9 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P: 0.13 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 7.9 ± 1.8 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 10.8 ± 2.1 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 2.3 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P *: 0.19 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P †: 0.0001 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt index a2b2125..cb9dae1 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt @@ -1,41 +1,39 @@ -CYP17 -C | Estimated allele frequency (%): 42.46 -C | Nonfounder statistic > Recessive model: - 1.01 -C | Nonfounder statistic > Dominant model: - 1.52 -C | Nonfounder statistic > Additive model: - 1.85 -C | Founder statistic > Recessive model: 0.40 -C | Founder statistic > Dominant model: 1.08 -C | Founder statistic > Additive model: 1.01 -P | Nonfounder statistic > Recessive model: 0.16 -P | Nonfounder statistic > Dominant model: 0.06 -P | Nonfounder statistic > Additive model: 0.03 -P | Founder statistic > Recessive model: 0.34 -P | Founder statistic > Dominant model: 0.14 -P | Founder statistic > Additive model: 0.16 -CYP19 -(TTTA) ≥10 | Estimated allele frequency (%): 33.71 -(TTTA) ≥10 | Nonfounder statistic > Recessive model: - 1.24 -(TTTA) ≥10 | Nonfounder statistic > Dominant model: 1.26 -(TTTA) ≥10 | Nonfounder statistic > Additive model: 0.32 -(TTTA) ≥10 | Founder statistic > Recessive model: - 0.32 -(TTTA) ≥10 | Founder statistic > Dominant model: 1.66 -(TTTA) ≥10 | Founder statistic > Additive model: 1.13 -P | Nonfounder statistic > Recessive model: 0.11 -P | Nonfounder statistic > Dominant model: 0.10 -P | Nonfounder statistic > Additive model: 0.38 -P | Founder statistic > Recessive model: 0.37 -P | Founder statistic > Dominant model: 0.05 -P | Founder statistic > Additive model: 0.13 -(TTTA) 11 | Estimated allele frequency (%): 28.78 -(TTTA) 11 | Nonfounder statistic > Recessive model: - 1.09 -(TTTA) 11 | Nonfounder statistic > Dominant model: 1.83 -(TTTA) 11 | Nonfounder statistic > Additive model: 0.97 -(TTTA) 11 | Founder statistic > Recessive model: - 1.50 -(TTTA) 11 | Founder statistic > Dominant model: 1.96 -(TTTA) 11 | Founder statistic > Additive model: 0.89 -P | Nonfounder statistic > Recessive model: 0.14 -P | Nonfounder statistic > Dominant model: 0.03 -P | Nonfounder statistic > Additive model: 0.17 -P | Founder statistic > Recessive model: 0.07 -P | Founder statistic > Dominant model: 0.03 -P | Founder statistic > Additive model: 0.19 \ No newline at end of file +CYP17 > C | Estimated allele frequency (%): 42.46 +CYP17 > C | Nonfounder statistic > Recessive model: - 1.01 +CYP17 > C | Nonfounder statistic > Dominant model: - 1.52 +CYP17 > C | Nonfounder statistic > Additive model: - 1.85 +CYP17 > C | Founder statistic > Recessive model: 0.40 +CYP17 > C | Founder statistic > Dominant model: 1.08 +CYP17 > C | Founder statistic > Additive model: 1.01 +CYP17 > P | Nonfounder statistic > Recessive model: 0.16 +CYP17 > P | Nonfounder statistic > Dominant model: 0.06 +CYP17 > P | Nonfounder statistic > Additive model: 0.03 +CYP17 > P | Founder statistic > Recessive model: 0.34 +CYP17 > P | Founder statistic > Dominant model: 0.14 +CYP17 > P | Founder statistic > Additive model: 0.16 +CYP19 > (TTTA) ≥10 | Estimated allele frequency (%): 33.71 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Recessive model: - 1.24 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Dominant model: 1.26 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Additive model: 0.32 +CYP19 > (TTTA) ≥10 | Founder statistic > Recessive model: - 0.32 +CYP19 > (TTTA) ≥10 | Founder statistic > Dominant model: 1.66 +CYP19 > (TTTA) ≥10 | Founder statistic > Additive model: 1.13 +CYP19 > P | Nonfounder statistic > Recessive model: 0.11 +CYP19 > P | Nonfounder statistic > Dominant model: 0.10 +CYP19 > P | Nonfounder statistic > Additive model: 0.38 +CYP19 > P | Founder statistic > Recessive model: 0.37 +CYP19 > P | Founder statistic > Dominant model: 0.05 +CYP19 > P | Founder statistic > Additive model: 0.13 +CYP19 > (TTTA) 11 | Estimated allele frequency (%): 28.78 +CYP19 > (TTTA) 11 | Nonfounder statistic > Recessive model: - 1.09 +CYP19 > (TTTA) 11 | Nonfounder statistic > Dominant model: 1.83 +CYP19 > (TTTA) 11 | Nonfounder statistic > Additive model: 0.97 +CYP19 > (TTTA) 11 | Founder statistic > Recessive model: - 1.50 +CYP19 > (TTTA) 11 | Founder statistic > Dominant model: 1.96 +CYP19 > (TTTA) 11 | Founder statistic > Additive model: 0.89 +CYP19 > P | Nonfounder statistic > Recessive model: 0.14 +CYP19 > P | Nonfounder statistic > Dominant model: 0.03 +CYP19 > P | Nonfounder statistic > Additive model: 0.17 +CYP19 > P | Founder statistic > Recessive model: 0.07 +CYP19 > P | Founder statistic > Dominant model: 0.03 +CYP19 > P | Founder statistic > Additive model: 0.19 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt index 3c6b95c..09122b0 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt @@ -19,11 +19,10 @@ VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > OR ( VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > P: - VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients ( n = 110): 79 VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 30 (37) -VAT -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > Number of patients ( n = 110): 55 -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 35 (63) -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > P: 0.001 -VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > OR (95% CI): 3.5 (1.5–8.3) -VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > P: 0.004 -VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients ( n = 110): 55 -VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 17 (30) \ No newline at end of file +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > Number of patients ( n = 110): 55 +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 35 (63) +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > P: 0.001 +VAT related to multidrug-resistant bacteria > VAT > Yes | Multivariate analysis > OR (95% CI): 3.5 (1.5–8.3) +VAT related to multidrug-resistant bacteria > VAT > Yes | Multivariate analysis > P: 0.004 +VAT related to multidrug-resistant bacteria > VAT > No | Univariate analysis > Number of patients ( n = 110): 55 +VAT related to multidrug-resistant bacteria > VAT > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 17 (30) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt index e4f0444..36caf83 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt @@ -37,8 +37,7 @@ Parameter | Population average > Estimate: Infusion (RSE %) Parameter | Population average > (RSE%) 1: Oral (RSE %) Parameter | Interindividual variability > Estimate %: Subcutaneous (RSE %) Parameter | Interindividual variability > (RSE%): IIV 3 (RSE %) -Residual error 2 -Proportional | Population average > Estimate: 0.191 (8.2) -Proportional | Population average > (RSE%) 1: 0.232(9.8) -Proportional | Interindividual variability > Estimate %: 0.162 (8.8) -Proportional | Interindividual variability > (RSE%): 24 (28) \ No newline at end of file +Residual error 2 > Proportional | Population average > Estimate: 0.191 (8.2) +Residual error 2 > Proportional | Population average > (RSE%) 1: 0.232(9.8) +Residual error 2 > Proportional | Interindividual variability > Estimate %: 0.162 (8.8) +Residual error 2 > Proportional | Interindividual variability > (RSE%): 24 (28) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt index 4838bfa..8989838 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt @@ -1,44 +1,40 @@ -Age at reference (years) -< 35 | Cases ( n = 506) > n: 62 -< 35 | Cases ( n = 506) > %: 12.3 -< 35 | Controls ( n = 459) > n: 80 -< 35 | Controls ( n = 459) > %: 17.4 -35+ | Cases ( n = 506) > n: 444 -35+ | Cases ( n = 506) > %: 87.7 -35+ | Controls ( n = 459) > n: 379 -35+ | Controls ( n = 459) > %: 82.6 -Race -White | Cases ( n = 506) > n: 450 -White | Cases ( n = 506) > %: 88.9 -White | Controls ( n = 459) > n: 412 -White | Controls ( n = 459) > %: 89.8 -Nonwhite | Cases ( n = 506) > n: 56 -Nonwhite | Cases ( n = 506) > %: 11.1 -Nonwhite | Controls ( n = 459) > n: 47 -Nonwhite | Controls ( n = 459) > %: 10.2 -Family history -None | Cases ( n = 506) > n: 280 -None | Cases ( n = 506) > %: 56.7 -None | Controls ( n = 459) > n: 294 -None | Controls ( n = 459) > %: 66.1 -First degree | Cases ( n = 506) > n: 94 -First degree | Cases ( n = 506) > %: 19.0 -First degree | Controls ( n = 459) > n: 36 -First degree | Controls ( n = 459) > %: 8.1 -Second degree | Cases ( n = 506) > n: 120 -Second degree | Cases ( n = 506) > %: 24.3 -Second degree | Controls ( n = 459) > n: 115 -Second degree | Controls ( n = 459) > %: 25.8 -Unknown | Cases ( n = 506) > n: 12 -Unknown | Controls ( n = 459) > n: 14 -Menopausal status -Premenopausal | Cases ( n = 506) > n: 445 -Premenopausal | Cases ( n = 506) > %: 88.3 -Premenopausal | Controls ( n = 459) > n: 392 -Premenopausal | Controls ( n = 459) > %: 85.8 -Postmenopausal | Cases ( n = 506) > n: 59 -Postmenopausal | Cases ( n = 506) > %: 11.7 -Postmenopausal | Controls ( n = 459) > n: 65 -Postmenopausal | Controls ( n = 459) > %: 14.2 -Unknown | Cases ( n = 506) > n: 2 -Unknown | Controls ( n = 459) > n: 2 \ No newline at end of file +Age at reference (years) > < 35 | Cases ( n = 506) > n: 62 +Age at reference (years) > < 35 | Cases ( n = 506) > %: 12.3 +Age at reference (years) > < 35 | Controls ( n = 459) > n: 80 +Age at reference (years) > < 35 | Controls ( n = 459) > %: 17.4 +Age at reference (years) > 35+ | Cases ( n = 506) > n: 444 +Age at reference (years) > 35+ | Cases ( n = 506) > %: 87.7 +Age at reference (years) > 35+ | Controls ( n = 459) > n: 379 +Age at reference (years) > 35+ | Controls ( n = 459) > %: 82.6 +Race > White | Cases ( n = 506) > n: 450 +Race > White | Cases ( n = 506) > %: 88.9 +Race > White | Controls ( n = 459) > n: 412 +Race > White | Controls ( n = 459) > %: 89.8 +Race > Nonwhite | Cases ( n = 506) > n: 56 +Race > Nonwhite | Cases ( n = 506) > %: 11.1 +Race > Nonwhite | Controls ( n = 459) > n: 47 +Race > Nonwhite | Controls ( n = 459) > %: 10.2 +Family history > None | Cases ( n = 506) > n: 280 +Family history > None | Cases ( n = 506) > %: 56.7 +Family history > None | Controls ( n = 459) > n: 294 +Family history > None | Controls ( n = 459) > %: 66.1 +Family history > First degree | Cases ( n = 506) > n: 94 +Family history > First degree | Cases ( n = 506) > %: 19.0 +Family history > First degree | Controls ( n = 459) > n: 36 +Family history > First degree | Controls ( n = 459) > %: 8.1 +Family history > Second degree | Cases ( n = 506) > n: 120 +Family history > Second degree | Cases ( n = 506) > %: 24.3 +Family history > Second degree | Controls ( n = 459) > n: 115 +Family history > Second degree | Controls ( n = 459) > %: 25.8 +Family history > Unknown | Cases ( n = 506) > n: 12 +Family history > Unknown | Controls ( n = 459) > n: 14 +Menopausal status > Premenopausal | Cases ( n = 506) > n: 445 +Menopausal status > Premenopausal | Cases ( n = 506) > %: 88.3 +Menopausal status > Premenopausal | Controls ( n = 459) > n: 392 +Menopausal status > Premenopausal | Controls ( n = 459) > %: 85.8 +Menopausal status > Postmenopausal | Cases ( n = 506) > n: 59 +Menopausal status > Postmenopausal | Cases ( n = 506) > %: 11.7 +Menopausal status > Postmenopausal | Controls ( n = 459) > n: 65 +Menopausal status > Postmenopausal | Controls ( n = 459) > %: 14.2 +Menopausal status > Unknown | Cases ( n = 506) > n: 2 +Menopausal status > Unknown | Controls ( n = 459) > n: 2 \ No newline at end of file diff --git a/pyproject.toml b/pyproject.toml index 10750b3..908a154 100644 --- a/pyproject.toml +++ b/pyproject.toml @@ -4,7 +4,7 @@ build-backend = "setuptools.build_meta" [project] name = "table2rules" -version = "0.6.0" +version = "0.6.1" description = "Convert HTML tables to flat, LLM-friendly rules using spatial pathfinding." readme = "README.md" license = "MIT" diff --git a/src/table2rules/_core.py b/src/table2rules/_core.py index 0a450b5..48889a9 100644 --- a/src/table2rules/_core.py +++ b/src/table2rules/_core.py @@ -211,6 +211,11 @@ def _build_rules(grid) -> List[LogicRule]: for row_idx in range(len(grid)): if row_idx in rows_with_value: continue + # A label-only row promoted to a row-group ancestor (scope="rowgroup") + # is threaded into the value lines beneath it — emitting it here too + # would duplicate it as an orphan label. + if any(grid[row_idx][c].get("scope") == "rowgroup" for c in range(n_cols)): + continue # Anchor the rule at the row's data column so it satisfies the quality # gate's "rules originate from " invariant. A row with no at # all is a true full-width divider — already handled as a @@ -319,6 +324,148 @@ def _next_band_below(after_row: int, min_colspan: int) -> int: grid[r][cc]["scope"] = "rowgroup" +def _mark_label_only_rowgroups(grid) -> None: + """Promote *label-only rows* to ```` so the maze threads + them into each value line's row path, the row-side counterpart of the + full-width band handled by :func:`_mark_rowgroup_bands`. + + A label-only row is a body row whose value (````) columns are all empty + while a leading label column carries text — the ``Label | Value`` form + pervasive in financial/insurance schedules (``9. Trip Cancellation | (empty)`` + above its value rows). Unlike a full-width band the label cell does *not* + span the value region; the other columns are simply empty, so + ``is_full_width_note`` geometry never sees it. Without this pass the row is + emitted as an orphaned ``is_label`` rule and the values beneath it lose their + group identity. + + Detection is geometric, not flag-based: a row with no value-bearing ```` + but exactly one non-empty body ```` label source cell. (Row-label + columns are already promoted to ```` upstream — Signal A/B/C + in grid_parser and simple_repair — so "no non-empty ````" means "no + value".) + + The single-label-cell requirement is what separates a group header from a + data row whose *designated* value columns merely happen to be empty. A genuine + group header carries one title ("9. Trip Cancellation", possibly spanning the + first N>1 columns via one ``colspan`` cell). A data row whose value columns + are blank ("Average: | 80.2 | 10.7 | 3.3", or a summary row under a header + that over-promoted numeric columns to row labels) spreads several distinct + values across its label cells — threading those as a group path would invent + a breadcrumb and misattribute it to the rows below. Such rows stay on the + ``is_label`` preservation path, unchanged. + + Stacking and extent (no content-aware level inference): + + * A maximal run of *consecutive* label-only rows forms one header stack. Its + members are threaded as nested ancestors in row order — a title followed by + a description (``10. Travel Delay`` then ``If the departure…``) both land in + the path, title first. + * A stack's extent runs from just below the stack down to the row before the + next stack OR the next full-width band, whichever comes first — so a group + never leaks into the next line-item or across a section divider. + * A stack is promoted only when its extent holds a real value row (parity + with the full-width-note guard): a trailing label that groups nothing is + left for the ``is_label`` preservation path, never stranded as an + empty-extent rowgroup. + + The stored ``rowgroup_extent_end`` is what the maze honors for these bands; + full-width bands keep their colspan-bounded extent. The two compose: a + section band (wider) and a label-only group (narrower) nest consistently. + """ + if not grid or not grid[0]: + return + n_rows = len(grid) + n_cols = len(grid[0]) + + def _is_body_row(r: int) -> bool: + return not any( + grid[r][c].get("is_thead") or grid[r][c].get("is_header_row") for c in range(n_cols) + ) + + def _has_value(r: int) -> bool: + return any( + grid[r][c]["type"] == "td" and (grid[r][c].get("text") or "").strip() + for c in range(n_cols) + ) + + def _label_cols(r: int) -> List[int]: + cols: List[int] = [] + for c in range(n_cols): + cell = grid[r][c] + if cell.get("is_thead") or cell.get("is_header_row"): + continue + if cell["type"] != "th": + continue + if cell.get("is_span_copy"): + # A span copy of a label cell originating in this same row is + # part of a multi-column label (label spans the first N>1 + # columns); promote it too. A span copy reaching down from a + # row above is not a label of this row. + origin = cell.get("origin", (r, c)) + if origin[0] != r: + continue + if not (grid[origin[0]][origin[1]].get("text") or "").strip(): + continue + elif not (cell.get("text") or "").strip(): + continue + cols.append(c) + return cols + + def _single_label_origin(r: int) -> bool: + # A group header is exactly one label source cell (a title, possibly + # colspan'd). More than one distinct non-empty label cell means a data + # row, not a divider — do not thread it. + origins = set() + for c in _label_cols(r): + cell = grid[r][c] + origins.add(cell.get("origin", (r, c)) if cell.get("is_span_copy") else (r, c)) + return len(origins) == 1 + + # A row already carrying a rowgroup cell (a full-width band promoted above, + # or a source scope="rowgroup") is a boundary, not a label-only candidate. + band_rows = { + r for r in range(n_rows) for c in range(n_cols) if grid[r][c].get("scope") == "rowgroup" + } + + is_label_row = [ + _is_body_row(r) + and r not in band_rows + and not _has_value(r) + and bool(_label_cols(r)) + and _single_label_origin(r) + for r in range(n_rows) + ] + + r = 0 + while r < n_rows: + if not is_label_row[r]: + r += 1 + continue + # Gather the maximal consecutive run of label-only rows. + s_start = r + while r + 1 < n_rows and is_label_row[r + 1]: + r += 1 + s_end = r + r += 1 # advance past the stack for the outer loop + + # Extent: down to the row before the next boundary (next label stack or + # full-width band). Bounded by a value row's presence. + extent_end = n_rows - 1 + for rr in range(s_end + 1, n_rows): + if is_label_row[rr] or rr in band_rows: + extent_end = rr - 1 + break + has_data_row = any(_has_value(rr) for rr in range(s_end + 1, extent_end + 1)) + if not has_data_row: + continue + + for rr in range(s_start, s_end + 1): + for c in _label_cols(rr): + grid[rr][c]["type"] = "th" + grid[rr][c]["scope"] = "rowgroup" + grid[rr][c]["rowgroup_extent_end"] = extent_end + + def _process_table_with_gate(table_html: str) -> Tuple[List[LogicRule], GateResult]: """Runs the full pipeline and returns rules plus the gate verdict. @@ -337,6 +484,7 @@ def _process_table_with_gate(table_html: str) -> Tuple[List[LogicRule], GateResu return [], GateResult(ok=False, score=0.0, reasons=["empty_grid"]) _mark_rowgroup_bands(grid) + _mark_label_only_rowgroups(grid) rules = clean_rules(_build_rules(grid)) gate = assess_confidence(grid, rules) if not gate.ok: diff --git a/src/table2rules/maze_pathfinder.py b/src/table2rules/maze_pathfinder.py index 87e335e..0e974c2 100644 --- a/src/table2rules/maze_pathfinder.py +++ b/src/table2rules/maze_pathfinder.py @@ -172,7 +172,14 @@ def find_headers_for_cell( origin_row, origin_col = origin my_colspan = origin_cell.get("colspan", 1) origin_rowspan = origin_cell.get("rowspan", 1) - if origin_rowspan > 1: + stored_extent = origin_cell.get("rowgroup_extent_end") + if stored_extent is not None: + # Label-only bands carry an explicit extent (the run of value + # rows they group, bounded by the next stack or section band), + # because their colspan=1 label cannot encode nesting depth the + # way a full-width band's width does. + extent_end = stored_extent + elif origin_rowspan > 1: extent_end = origin_row + origin_rowspan - 1 else: extent_end = len(grid) - 1 diff --git a/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md b/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md new file mode 100644 index 0000000..7acca26 --- /dev/null +++ b/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md @@ -0,0 +1,20 @@ + + + + + + + + + + + +
AB
Region X
AsiaJapan1020
AsiaKorea3040
Totaln=4
diff --git a/tests/fixtures/matrix/label-only-rowgroup.md b/tests/fixtures/matrix/label-only-rowgroup.md new file mode 100644 index 0000000..a0e224b --- /dev/null +++ b/tests/fixtures/matrix/label-only-rowgroup.md @@ -0,0 +1,27 @@ + + + + + + + + + + + + + + + +
BenefitMaximum limit (S$)
Value PlanEconomy Plan
9. Trip Cancellation
If the trip is cancelled5,00010,000
10. Travel Delay
If the departure is delayed
1. Adult insured person100150
2. Child insured person5075
11. Trip Postponement